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ABSTRACT 
Elizabeth Parker Merricks:  Cardiovascular Disease, Endothelial Cell Gene 
Expression, and Renal Dysfunction in Insulin Resistant, Hyperlipidemic Swine 
(Under the direction of Timothy C. Nichols, M.D.) 
 
Globally, the prevalence of insulin resistant (IR), type-2 diabetes mellitus (DM) is 
increasing.  Both IR and DM are associated with an increase in cardiovascular 
events and renal pathology.  The underlying cause for this increase is, as yet, not 
completely understood.  A thoroughly characterized model is needed to identify 
mechanisms connecting insulin resistance with cardiovascular and renal disease.  
Through selective breeding we have produced hyperinsulinemic pigs that develop 
hypercholesterolemia when fed a high fat diet. A subgroup of these pigs develops 
severe and diffuse proximal and distal abdominal aorta and coronary artery 
atherosclerosis compared to the other group which has moderate disease. Through 
aortic endothelial cell gene expression studies we have identified three genes 
(MERP-1, RABGAP1L, COL12A1) that are uniquely expressed in the atherosclerotic 
endothelium of the severe disease group. Additionally, a subgroup of the pigs 
develops renal histopathology that mirrors the phenotype of an insulin 
resistant/diabetic nephropathy when albuminuria is present.  All pigs have been 
monitored over the course of one year on a high fat, high sodium diet for weight, 
backfat, blood pressure, insulin sensitivity, total and LDL cholesterol, triglycerides, 
oxidized LDL, fructosamine, inflammatory makers, and aldosterone.  The goals of 
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this proposal were to characterize this pig model with regards to 1- presence and 
severity of coronary and aortic atherosclerosis and its association with markers of 
oxidative stress, 2-changes in endothelial cell gene expression as it relates to the 
severity of aortic atherosclerosis, and 3-extent of renal pathology and its 
resemblance to human diabetic renal disease. This will support the long range goal 
of this laboratory, which is to provide the scientific community with a well-
characterized, useful animal model of insulin resistance and/or type-2 diabetes, 
which develops human-like coronary and aortic atherosclerosis and IR/diabetic like 
nephropathy. 
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 Chapter 1 
 
Introduction 
Insulin resistance (IR) is defined as a condition where there is a decreased 
biological response to normal concentrations of serum insulin.  The body is able to 
produce insulin, but there is improper use of insulin by muscle, fat, and liver cells in 
the conversion of glucose to energy.   This often results in a compensatory insulin 
secretion by the pancreas which leads to increased insulin in the blood.  IR generally 
has no symptoms, may be present for years without detection, and is commonly a 
precursor of diabetes mellitus (DM).  When the pancreas can no longer compensate 
for the needed increase in insulin, glucose increases as well.  Patients with high 
normal glucose and increased insulin are in a “pre-diabetic” state.  According to the 
United States Department of Health and Human Services, pre-diabetes is on the rise 
in the US.  Many of these patients go on to develop DM.  The incidence of insulin 
resistant, type 2 DM is increasing at epidemic rates globally.  In the United States 
alone, in 2007, there were 1.6 million new cases of diabetes diagnosed in people 
aged 20 years or older and a total of 7.8 percent of the population with diabetes.[1] 
According to the International Diabetes Federation, the number of people living with 
diabetes in 2010 is expected to reach 285 million worldwide.[2] 
For insulin resistance alone, the prevalence among those 20 years or older 
may be as much as 34%.[3] Obesity is not only a major risk factor for insulin 
 
 
resistance but may also add to its severity. During obesity there may be 
dysregulated release of non-esterified fatty acids, glycerol, hormones, and 
proinflammatory cytokines from adipose tissue which may contribute to the 
development of IR.[4, 5] Additionally, insulin resistance may contribute to the 
development of obesity[6] as adipocytes are highly responsive to insulin.  In the last 
25 years there has been a drastic rise in obesity among adults in the United States 
with >30% of the adult population now considered obese.[7] 
 
Insulin Resistance, Endothelial Dysfunction and Cardiovascular Disease 
Normal, healthy endothelium has numerous beneficial effects, including: 
promotion of vasodilation; antioxidant, anti-inflammatory, anticoagulant, and 
profibrinolytic effects; and inhibition of leukocyte adhesion and migration, smooth 
muscle cell proliferation and migration, and platelet aggregation and adhesion.[8]  
Endothelial dysfunction, while an early and potentially reversible step, can lead to 
the initiation and progression of atherosclerosis. 
Atherosclerosis is the basis of cardiovascular disease (CVD) - the leading 
cause of death in the world today.[9]  Atherosclerosis is a process that occurs in 
large to medium sized arteries.  Mass transport, low density lipoprotein (LDL) 
receptors, and damage to the endothelium allow the accumulation of LDL in the 
vessel wall where it is then oxidized.  Damaged endothelium also allows adhesion of 
platelets and monocytes.  Monocytes migrate into the subendothelial space, 
transform to macrophages, and phagocytize oxLDL to become foam cells.  Both 
platelets and macrophages secrete factors that activate smooth muscle cells to 
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migrate from the media to the intima, where they can proliferate and form a fibrous 
cap over the plaque. The arterial walls thicken and lose their elasticity. 
 Atherosclerosis is a complicated process.  The initial step is thought to be 
chronic endothelial injury, leading to endothelial dysfunction.  This dysfunction can 
be brought about by diabetes and a number of risk factors including hypertension, 
smoking, viruses, and immune reactions, but the two key factors are thought to be 
hyperlipidemia and hemodynamic disturbances.  While atherosclerosis most often 
occurs in the arteries supplying the heart, it also occurs in arteries supplying the 
brain, kidneys, and lower extremities. 
The progression of endothelium from normal to dysfunctional to 
atherosclerotic may parallel the progression of insulin resistance to overt 
diabetes.[10]  Studies have shown that insulin resistance co-associates with other 
factors that lead to endothelial dysfunction, especially changes in lipoproteins.[11]  
Insulin works through both the phosphatidylinositol 3-kinase pathway to regulate 
endothelial nitric oxide (NO) production and as a growth factor through the mitogen 
activated protein kinase (MAPK) pathway to affect cell growth and movement, 
increase endothelial cell adhesion markers and mediate expression of certain 
prothrombotic factors.[11]   
Numerous large population studies have shown that both IR and DM are 
associated with an increase in cardiovascular events.[12-18]  However, the 
underlying cause for this increase is, as yet, not completely understood.   
 
Insulin Resistance and Nephropathology 
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Hypercholesterolemia and hypertension (key risk factors for atherosclerosis) 
as well as obesity, insulin resistance and diabetes affect renal function. Endothelial 
dysfunction may also play a significant role in insulin resistance and diabetic renal 
complications.  Insulin resistance and hyperinsulinemia have been independently 
associated with chronic kidney disease in numerous analyses[19].  Insulin is thought 
to alter urinary sodium excretion by effects on the tubules, to promote mesangial cell 
proliferation, and increase the action of angiotensin II.[19] One study found patients 
receiving peritoneal dialysis have an increase in insulin levels and insulin resistance 
when compared to healthy controls.[20]    A ten year follow-up community based 
study found obesity, amongst other factors, to be a predictor of chronic kidney 
disease.[21] This finding is thought to be mediated through insulin resistance and 
endothelial dysfunction.[22] Insulin resistance itself may be an independent predictor 
of the development of nephropathy in diabetics. 
 
Pigs as Model of Human Disease 
A thoroughly characterized model is needed to investigate the connection 
between insulin resistance and cardiovascular disease and nephropathy.  Pigs have 
long provided experimental models of human disease.  Swine have many 
phenotypic similarities to humans including cardiovascular anatomy and function, 
renal architecture and function, metabolism, lipoprotein profile, size, tendency to 
obesity, and omnivorous habits.  Swine are also similar to humans in that they carry 
a large part of cholesterol in LDL and develop atherosclerosis with aging.  The 
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phenotypic susceptibility to coronary atherosclerosis makes pigs an attractive 
species for related mechanistic studies.   
 
Dissertation Overview 
Through selective breeding, our group has developed a hyperinsulinemic pig 
model that develops worsening insulin resistance when fed a high fat diet for twelve 
months.  A subgroup of these pigs develops severe and diffuse proximal and distal 
abdominal aorta and coronary artery atherosclerosis compared to the other group 
which has moderate disease.  Additionally, a subgroup of these pigs develops 
albuminuria which appears to predict the presence of renal histopathological 
changes that are consistent with those seen in IR/diabetic humans.  In the current 
studies, all pigs have been monitored over the course of one year on a high fat diet 
for weight, backfat, blood pressure, insulin sensitivity, total and LDL cholesterol, 
triglycerides, oxidized LDL, fructosamine, inflammatory makers, and aldosterone.  
Changes in specific markers of oxidative stress have been identified in these 
animals.   
Several swine models of both type I and II diabetes are being explored.   A 
recent comprehensive review by our group explains the available swine models of 
type 2 DM and/or IR.[23]  This review also lists steps for validating a model of type 2 
IR-DM. The model presented in this dissertation addresses these steps including 
documentation of fasting hyperinsulinemia, insulin sensitivity, serum glucose levels, 
body fat measurements, lipoprotein concentrations, serum markers, blood pressure 
and end-organ damage.  
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The overall goal of this dissertation is to characterize these pigs with regards 
to cardiovascular disease, changes in endothelial cell gene expression, and renal 
pathology as related to insulin resistance and obesity and the similarity of each to 
what is seen in human disease.  This will support the long range goal of this 
laboratory, which is to provide the scientific community with a well-characterized, 
useful animal model of insulin resistance and/or type-2 diabetes, which develops 
human-like coronary and aortic atherosclerosis as well as nephropathology. 
 
 Chapter 2  
Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet 
 
 
Abstract 
Objective: To investigate if the severity of atherosclerosis that develops in 
pigs fed a high fat/high NaCl diet is associated with elevated oxLDL, fructosamine, 
and aldosterone.  Methods and Results: The primary endpoint was atherosclerosis 
severity in adult pigs (n= 18) fed a high fat diet that also contained high NaCl (56% 
above recommended levels) for 1 year. Nine pigs developed severe and diffuse 
distal coronary atherosclerosis (i.e., intimal area as percent medial area ≥ 75% in at 
least 2 sections = severe and ≥ 75% over 3 sections separated by 2 cm in the distal 
half of the coronary artery = diffuse distal) and proximal abdominal aortic 
atherosclerosis that was severe (i.e., ≥ 6 mm2 intimal area) and diffuse (i.e., ≥ 40 % 
surface with raised lesions). The other nine pigs had moderate atherosclerosis. Both 
groups of pigs developed comparable elevations in total and LDL and HDL 
cholesterol, weight gain, increase in backfat, blood pressure, and inflammatory 
markers, and increase in insulin resistance (Bergman Si, p ≤ 0.008) without overt 
diabetes. Insulin resistance did not correlate with atherosclerosis severity. Most 
importantly, when compared to the 9 pigs with moderate atherosclerosis, the 9 pigs 
 
 
with severe and diffuse atherosclerosis had significantly higher oxLDL and greater 
increases in fructosamine and aldosterone values consistent with increased 
oxidative stress. 
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Introduction 
The increasing prevalence of insulin resistance and type 2 diabetes is likely to 
be attended by a significant increase in cardiovascular disease (CVD).[24-26]  
Insulin resistance (IR) is defined as a decreased biological response to normal 
concentrations of serum insulin that over time leads to compensatory 
hyperinsulinemia.[25]  Insulin resistant and diabetic humans often develop diffuse 
coronary atherosclerosis involving long arterial segments and including multiple 
distal lesions.[27-31]  These patients require intensive medical therapy and their 
lesions are less amenable to angioplasty, stent placement, surgical reconstruction or 
bypass.[32, 33]  Often disease progression outside of the stented segment of the 
coronary artery or bypass insertion site limits the duration of benefit in patients with 
IR and diabetes and even the most aggressive medical treatment regimens do not 
lower the risk for CVD to the non-diabetic level.[33-36]  These findings strongly 
suggest that available treatments are not addressing key pathophysiological 
mechanisms that, when activated in these patients, augment the development of 
atherosclerosis. Thus, there is a need for relevant animal models of both insulin 
resistance and type 2 diabetes that also exhibit severe and diffuse coronary and 
aortic atherosclerosis.  
Animal model systems with coexistent diabetes and hyperlipidemia have 
been developed in mice, rabbits, non-human primates and pigs in an attempt to 
determine the effect of hyperglycemia and/or insulin resistance on the development 
of atherosclerosis.[35, 36]  In general, injection of streptozotocin has been used to 
create a model of type 1 diabetes.[37]  Often this drug has been given to APO E or 
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LDL receptor deficient mice to produce a combined model that is predisposed to 
aortic atherogenesis.[38, 39]  These mice develop subintimal deposition of lipid and 
oxidized LDL and inflammatory cell infiltrates,[40] but  their degree of smooth muscle 
cell hyperplasia and other characteristics of advanced atherosclerotic lesion 
development are not similar to human lesions.[41] Furthermore correlations between 
metabolic changes and hyperlipidemia with severity of atherosclerosis progression 
have not been established therefore attributing changes in lesion severity to 
changes in either hyperglycemia or insulin resistance independent of changes in 
cholesterol has been difficult.[42]   
Models of type 2 diabetes have been more difficult to generate. OB/OB (leptin 
deficient) mice and db/db (leptin receptor mutation) mice have been crossed with 
APO E deficient or LDL receptor knockout mice, which if fed a western diet develop 
more severe insulin resistance and type 2 diabetes.[43]  However proving that the 
presence of more severe insulin resistance or diabetes in these animals is the sole 
cause of increased atherosclerosis has been difficult since an increase in 
hyperlipidemia is occurring simultaneously.[44]  Diabetic rabbits and pigs have also 
been studied but to a much lesser extent.[45-49]  In both cases these models have 
used either Alloxan or streptozotocin for inducing diabetes and then fed high fat 
diets.  These models also have had difficulty determining the extent to which 
atherosclerosis is increased due to the induction of diabetes as opposed to 
lipoprotein abnormalities.[41] One study showed substantial differences in coronary 
and aortic atherosclerosis but the interpretation was confounded by concomitant 
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changes in the severity of the lipoprotein phenotype and whether the animals had 
extensive distal coronary atherosclerosis was not reported in detail.[49] 
Our objective was to investigate how severity of atherosclerosis is associated 
not only with lipoproteins, weight, blood pressure, inflammatory markers and severity 
of IR in an animal model but also changes in parameters that correlate with change 
in oxidative stress.  Our experimental approach was to study normocholesterolemic 
pigs fed a high fat diet that also contained increased NaCl. The results show that the 
experimental pigs developed varying degrees of atherosclerosis which were grouped 
as moderate or severe. Atherosclerosis severity was not associated with increases 
in body weight, backfat, insulin or glucose levels, insulin resistance, total or LDL or 
HDL cholesterol levels, blood pressure, or inflammatory markers.  Three other 
variables, however, that have been associated with increased oxidative stress, (i.e. 
oxLDL, fructosamine, and aldosterone) were found to be significantly higher in 
animals with the severe atherosclerosis phenotype as compared to animals with less 
severe disease.  Thus, our paradigm suggests that feeding a high fat/high NaCl diet 
may enhance the severity of atherosclerosis development through changes in 
oxidative stress in insulin resistant, hypercholesterolemic pigs.  
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METHODS 
Experimental Pigs, High Fat/High NaCl Diet, and Sampling Protocol during Year 
Long Study 
All pigs were treated according to the standards set in the Guide for Care and 
Use of Laboratory Animals (National Institutes of Health publication No. 85-23).  All 
procedures and protocols were in accordance with institutional guidelines and 
approved by the Institutional Animal Care and Use Committee. All pigs were 
produced and maintained in the same environmental conditions at the Francis Owen 
Blood Research Laboratory at the University of North Carolina at Chapel Hill and are 
from Spotted Poland/China and Yorkshire crosses. Pigs from the following two 
genotypes were used: normocholesterolemic (n=10), heterozygous familial 
hypercholesterolemic (FH)  that are also normocholesterolemic at baseline 
(n=8).[50-52]  Neither normocholesterolemic nor heterozygous FH pigs exhibit 
hypercholesterolemia unless they are fed a high fat diet.  Eighteen pigs were 
entered into the year-long study as they became available (11 males, 7 females) and 
the entire group was studied over 24 months. The mean age at study entry was 3.9 
± 2 yr.  All study pigs were fed a high fat diet that consisted of pig chow (5NP8 
Wayne™ 15% Pig & Sow Pellets, Granville Milling, Granville NC) supplemented with 
1% cholesterol, 20% beef tallow, and 0.75% cholate by weight.[53, 54]  The NaCl 
content of the diets was measured (Eurofins Scientific Inc, Des Moines, IA) and 
5NP8 provided 0.35% or 8 grams/day as recommended[55] and the high fat diet 
provided 0.55% or 12.5 grams/day, a 56% increase.  The total calories in the high 
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fat/high NaCl diet were distributed as: 43% fat, 12.5% protein, and 44.5% 
carbohydrate. Weight, backfat, blood pressure, total and LDL and HDL cholesterol, 
oxLDL, fructosamine, aldosterone, triglycerides, Bergman Frequently Sampled 
Intravenous Glucose Tolerance Test (FSIVGTT), and serum and plasma 
inflammatory markers (TNF-alpha, IL-6, PAI-1, CRP) were obtained at baseline (BL), 
3, 6, and 12 months of the year-long study. Serum glucose was measured monthly 
while the pig was fully conscious in addition to when it was sedated for the Bergman 
FSIVGTT.   At study termination all pigs were euthanized with an overdose of 
pentobarbital (6 grains/10 lbs. IV) and tissue samples for morphometry were 
collected from all three coronary arteries and the abdominal aorta. 
 
Bergman Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT).  
Each pig was sedated with ketamine 4-6 mg/kg intramuscular (IM) and 
acepromazine 0.1-0.3 mg/kg IM.  Two intravenous catheters were placed, one for 
sampling and one for infusing glucose and insulin.  A bolus of glucose (0.3 gm/kg IV) 
was administered as a 50% solution over ~5 to 10 min.  Serum was prepared from 
blood samples obtained at   -15, -10, -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, and 19 minutes to 
measure insulin and glucose concentrations.  At 20 minutes, an insulin bolus 
(0.03U/kg IV, Novolin R Human Insulin Regular, Novo Nordisk) was injected and 
blood samples for insulin and glucose concentrations were collected at 22, 25, 30, 
40, 50, 70, 100, 140, and 180 minutes.  The data were analyzed by the Bergman 
method to calculate an insulin sensitivity index (Si) using MINMOD Millennium 
version 6.02.[56]  This method has been widely used to estimate insulin 
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sensitivity.[57-61]  
 
Measurement of Body Weight, Backfat, and Arterial Blood Pressure 
Pigs were weighed on a FlexWeigh scale (model LPF-4824) with a digital 
readout (Velcon/FlexWeigh Model 5). Backfat has been used as an index of total 
body fat in pigs[62-67] and was measured by ultrasound over the last rib with the pig 
standing (Fukuda Denshi, model UF750XT). The intra-animal variability is < 7%.  
Arterial blood pressure was measured in the tail of conscious pigs (Veterinary Blood 
Pressure Monitor, model 9301V, CAS Medical Systems, Inc).[68-70]  The results are 
the mean of 5 measurements taken over 5 min.   
 
Total and LDL and HDL cholesterol, triglycerides, insulin, and glucose 
Serum cholesterol and triglycerides were measured by an automated method 
(ANTECH® Inc. Cary, NC)[53].  LDL and HDL cholesterol were measured by 
colorimetric endpoint reactions using the Liquid Direct LDL and HDL Cholesterol 
Kits, respectively (Amresco, Solon, OH).  Reactions were performed according to 
the manufacturer’s instructions modified for a 96 well plate and optical density was 
read using a Vmax kinetic microtiter plate reader (Molecular Devices).  Serum insulin 
was measured by a solid phase RIA (ICN, lower unit of detection is 2 µU/ml). The 
intraassay variability was 4% and the interassay variability was 6%. Serum glucose 
was measured with a 2300 STAT PLUS (YSI, Yellow Springs, Ohio). 
 
Inflammatory Markers, oxLDL, Fructosamine, and Aldosterone 
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Pig specific ELISAs were used according to the manufacturer’s instructions to 
measure  TNF-alpha (Biosource),[71]  IL-6 (R&D Systems),  PAI-1 (Molecular 
Innovations, Southfield, MI),[72] CRP (Pig CRP, Tri-Delta Diagnostics), and oxLDL 
(Mercodia, Uppsala, Sweden).[73-75]  Fructosamine was measured in serum by a 
colorimetric endpoint reaction according to the manufacturer’s instructions 
(Raichem, San Diego, CA). Aldosterone was measured by enzyme immunoassay 
with a commercially available kit (Aldosterone EIA, Alpco Diagnostics, Salem, NH) 
using serum samples that were ether extracted, dried and reconstituted in sample 
buffer.  
 
Morphometry of Coronary and Abdominal Aortic Atherosclerosis 
Coronary artery and aortic atherosclerosis were measured as described 
previously.[54, 76]  
 
Definition of Severe and Diffuse Distal Coronary Artery and Abdominal Aortic 
Atherosclerosis 
Severe coronary atherosclerosis was defined as mean intimal area as a 
percent of medial area of ≥ 75 % in at least two coronary artery cross sections.  
Severe and diffuse distal coronary atherosclerosis was defined as a mean intimal 
area as a percent of medial area of ≥ 75% over three coronary artery cross sections 
separated by 2 cm in the distal half of the coronary artery. 
Abdominal aortic atherosclerosis in swine and humans begins at the aortoiliac 
junction and progresses in a retrograde fashion.[77-81]  Severe abdominal aortic 
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atherosclerosis was defined as the proximal half having a mean intimal area of ≥ 3.5 
mm2 and diffuse abdominal aortic atherosclerosis was defined as the proximal half 
having ≥ 40% of the surface area covered with raised lesions. 
 
Total IEL Area as an Assessment of Coronary Artery Remodeling  
The total area contained within the IEL has been used to assess coronary 
arteries for remodeling during atherogenesis in humans and pigs.[28, 82, 83]  Thus, 
the total IEL area for all three coronary arteries from the two groups of pigs was 
measured as described[54, 76] and the results were expressed in mm2 for each of 
the three arteries from all pigs.  
 
Percent of Coronary Artery Cross Sections with Fibrous Caps and Measurement of 
Fibrous Cap Thickness 
The presence or absence of a fibrous cap was determined from visual 
inspection of all sections of each coronary artery from all pigs.  The results are 
expressed as the percent of cross sections with fibrous caps.  Maximal fibrous cap 
thickness was measured on the cross section with the greatest percent stenosis for 
a given coronary artery and is expressed in mm.  
 
Statistical Analysis  
For all groups, descriptive statistics are reported as means ± SD for weight, 
backfat, blood pressure, triglycerides, total and LDL and HDL cholesterol, oxLDL, 
fructosamine, aldosterone, inflammatory markers, insulin, glucose, Bergman Si 
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values, coronary and aortic atherosclerosis measurements. The Wilcoxon rank sum 
statistic was used as the primary method for comparisons between two groups for 
coronary and aortic atherosclerosis measurements.  Parametric repeated measures 
ANOVA/ANCOVA models with group, time, and baseline as explanatory factors 
were used as the primary method for oxLDL (as logarithms), fructosamine, and 
aldosterone (as logarithms).  For all other variables, Wilcoxon rank sum statistics for 
comparisons between groups and Wilcoxon signed ranks statistics for comparisons 
within groups were used with parametric repeated measures ANOVA/ANCOVA 
models in mutually supportive ways and with comparable results for blood pressure, 
total and LDL and HDL cholesterol, and triglycerides.  The ANOVA/ANCOVA models 
additionally included gender. A p-value being less than 0.05 was the criterion for 
identifying a change within groups, a difference between groups, or an association of 
interest for future investigation. 
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Results 
The detailed results of the atherosclerosis data are presented first followed by 
the metabolic parameters that were monitored during the year-long study to 
determine which were associated with the development of either the severe and 
diffuse versus moderate atherosclerosis phenotype. Additional analyses that 
assessed the effect of gender and genotype (i.e., normocholesterolemic and FH 
heterozygous) had similar results.  
 
Severity of Coronary Artery Atherosclerosis   
At the end of the study, the pigs were found to have developed two different 
degrees of atherosclerosis severity: Severe = severe and diffuse atherosclerosis, n = 
9 (4 males and 5 females), age 4.7 ± 1.9 years old; and Moderate = moderate 
atherosclerosis, n = 9 (7 males and 2 females), age 5.0 ± 2.3 years). 
The nine pigs meeting the criteria for severe atherosclerosis were found to 
have a mean intimal area as a percent medial area ≥ 75% in all but one RCA and all 
but one LAD cross section (Figure 2.1). The mean intimal area as a percent medial 
area in the distal half of the coronary arteries for all 9 pigs in this group was ≥ 75% in 
at least 3 consecutive cross sections over 2 cm in all three coronary arteries (Figure 
2.1).  When the extent of coronary atherosclerosis was compared between the 
severe and moderate atherosclerosis groups for the proximal and distal halves of the 
coronary arteries, the severe group had significantly larger intimal area, percent 
stenosis, and intimal area as a percent medial area (Figures 2.1 and 2.2 and Table 
2.1, p<0.001). 
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 Coronary Artery Remodeling Assessed by Total IEL Area 
The severe atherosclerosis group had significantly larger total IEL areas when 
compared to the moderate group for all three coronary arteries (Table 2.2, p<0.01). 
These data are consistent with a greater degree of positive remodeling.[28, 82, 83]  
There was no evidence of pair wise vessel to vessel differences in the total IEL area 
within either group (p>0.10).  
 
Percent of Coronary Artery Cross Sections with Fibrous Caps  
The percent of coronary artery cross sections containing fibrous caps was 
significantly greater in the severe atherosclerosis group for all three coronaries 
(Table 2.2, p<0.01). There was no evidence among animals with detectible fibrous 
caps of differences between the mean fibrous cap thickness for the groups (p>0.05).  
 
Severity of Abdominal Aortic Atherosclerosis   
The animals that had severe coronary disease also had an average intimal 
area of 6.6 ± 5.4 mm2 in the proximal half of the abdominal aorta, and therefore had 
severe aortic atherosclerosis (Table 2.3). They also had an average of 59.4 ± 21.3 
% surface area in the proximal half covered by raised lesions, and therefore had 
diffuse disease (Table 2.4).  The pigs with moderate disease had a significantly 
lower (p = 0.003) percent surface area covered by raised lesions in the proximal half 
(23.0 ± 8.5%, Table 2.4).  Likewise, the intimal area was significantly less (p = 0.034) 
than the severe atherosclerosis group (2.5 ± 4.1 compared to 6.6 ± 5.4 mm2). The 
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pigs with severe atherosclerosis also had significantly greater intimal area as a 
percent of medial area for the proximal half of the abdominal aorta compared to the 
moderate group (Table 2.3, 16.8 ± 9.2 compared to 7.0 ± 11.8, p = 0.027).  
Differences between the groups for the distal half of the abdominal aorta tended to 
be absent or less evident than those for the proximal half. 
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Figure 2.1. Intimal Area as % Medial Area from Serial Coronary Artery 
Sections.  The mean ± SD for intimal area as % medial area of all sections from all 
three coronary arteries are shown by severe (black) or moderate (white) 
atherosclerosis phenotypes.  Sections were taken at 1 cm intervals. The solid black 
vertical line indicates the division between the proximal and distal halves of each 
coronary artery. The horizontal dashed line = 75%, the criteria for severe coronary 
atherosclerosis. The presence of lesions with a value of ≥ 75% over 3 sections (i.e., 
2 cm) in the distal half was defined as severe and diffuse distal disease.  Using this 
definition, pigs in the severe atherosclerosis group exhibited severe and diffuse 
distal coronary atherosclerosis in all three coronary arteries. 
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Figure 2.2. Coronary Artery Atherosclerosis in Insulin Resistant Pigs. Panels 
A1 to A5: Representative serial sections from the proximal to distal left anterior 
descending coronary artery are shown from an IR pig with severe and diffuse distal 
coronary atherosclerosis. The mean intimal area as a percent of medial area for all 
three coronary arteries for this pig (35G) was 203.9% proximally and 338.5% 
distally. Panels B1 to B5: In contrast, a pig (05I) with moderate coronary 
atherosclerosis had a mean intimal area as a percent of medial area for all three 
coronary arteries of 11.3% proximally and 5.8% distally. Features of coronary 
atherosclerosis in rows A and B are shown at higher magnification in rows C and D, 
respectively: intimal thickening (IT) and calcification in a pig with moderate 
atherosclerosis (Ca2+ (moderate), Panels B1 and D1), calcification in a pig with 
severe atherosclerosis (Ca2+ (severe), Panels A4 and C2), fibrous cap (FC, Panel 
A2 and C1), hemorrhage into the plaque (H, Panels A4 and C3), medial thinning 
(MT, Panels A4 and D2), necrosis (N, Panels A4 and D3). (Hematoxylin and Eosin, 
mag bar = 500 µm is shown in B5 for rows A and B; mag bar = 10 µm in all panels in 
rows C and D). 
 Table 2.1. Proximal and Distal Coronary Artery Atherosclerosis Morphometry 
in IR Pigs 
    
 
Severe 
Atherosclerosis 
(n = 9) 
Moderate 
Atherosclerosis 
(n = 9) 
p* 
   
Proximal Coronary Arteries    
Medial area (mm2) 7.8 ± 1.2 7.1 ± 2.4 0.480 
Intimal area (mm2) 5.9 ± 2.2 1.6 ± 1.4 0.001 
% stenosis 60.7 ± 11.3 23.2 ± 13.8 < 0.001
Intimal area as % medial area 98.0 ± 47.2 21.9 ± 14.5 < 0.001
    
Distal Coronary Arteries    
Medial area (mm2) 3.8 ± 1.1 3.3 ± 1.5 0.380 
Intimal area (mm2) 6.3 ± 2.4 1.3 ± 1.0 < 0.001
% stenosis 83.3 ± 6.4 32.4 ± 19.1 < 0.001
Intimal area as % medial area 185.5 ± 73.6 36.2 ± 22.5 < 0.001
    
* Wilcoxon rank sum statistic for differences between groups 
25 
 26
Table 2.2. Mean Coronary Artery Total IEL Area (mm2), Percent of Coronary 
Artery Cross Sections Containing Fibrous Caps, and Fibrous Cap Thickness 
(mm) in IR Pigs 
     
 
Severe 
Atherosclerosis 
(n = 9) 
Moderate 
Atherosclerosis 
(n = 9) 
 p† 
     
Right     
Total IEL area 8.62 ± 2.12 5.30 ± 1.60  0.008 
% with Fibrous Cap 74.1 ± 17.1 21.3 ± 17.1  0.001 
Fibrous Cap Thickness 0.591 ± 0.168 0.412 ± 0.165  0.06 
  (n = 8)*   
     
Circumflex     
Total IEL area 7.39 ± 2.55 3.86 ± 1.89  0.008 
% with Fibrous Cap 90.0 ± 15.6 32.4 ± 39.8  0.006 
Fibrous Cap Thickness 0.658 ± 0.241 0.442 ± 0.271  0.35 
  (n = 5)*   
     
Left Anterior Descending     
Total IEL area 8.64 ± 2.25 4.84 ± 2.71  0.006 
% with Fibrous Cap 83.6 ± 17.8 22.2 ± 32.3  0.002 
Fibrous Cap Thickness 0.461 ± 0.096 0.322 ± 0.140  0.11 
  (n = 5)*   
     
* The difference in “n” values for Fibrous Cap Thickness reflects the absence of 
detectible fibrous caps in the respective artery from a given pig. 
†Wilcoxon rank sum statistic for differences between groups 
 Table 2.3.  Proximal and Distal Abdominal Aortic Atherosclerosis Morphometry 
in IR Pigs 
      
Histomorphometry 
Severe 
Atherosclerosis 
(n = 9) 
Moderate 
Atherosclerosis 
(n = 9) 
p* 
     
Proximal Half Abdominal Aorta     
Medial area (mm2) 35.0 ± 13.2  36.9 ± 9.7 0.427 
Intimal area (mm2) 6.6 ± 5.4  2.5 ± 4.1 0.034 
Intimal area as % medial area 16.8 ± 9.2  7.0 ± 11.8 0.027 
     
Distal Half Abdominal Aorta    
Medial area (mm2) 40.1 ± 14.8  33.4 ± 9.5 0.427 
Intimal area (mm2) 8.0 ± 4.4  4.4 ± 4.9 0.052 
Intimal area as % medial area 19.2 ± 8.2  12.7 ± 14.1 0.064 
      
* Wilcoxon rank sum statistic for differences between groups 
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Table 2.4.  Proximal and Distal Abdominal Aortic Atherosclerosis Morphometry 
in IR Pigs 
      
En Face Measurements 
Severe 
Atherosclerosis 
(n = 9) 
Moderate 
Atherosclerosis 
(n = 9) 
p* 
     
Proximal Half Abdominal Aorta     
Total aortic surface area (cm2) 15.9 ± 2.9  15.0 ± 3.6 0.536 
Area with raised lesion (cm2) 9.7 ± 4.6  3.5 ± 1.6 0.005 
% aortic surface with raised 
lesions 59.4 ± 21.3  23.0 ± 8.5 0.003 
     
Distal Half Abdominal Aorta    
Total aortic surface area (cm2) 15.3 ± 3.9  15.0 ± 4.1 0.791 
Area with raised lesion (cm2) 11.0 ± 4.7  7.9 ± 4.2 0.216 
% aortic surface with raised 
lesions 68.9 ± 16.0  51.0 ± 18.8 0.077 
      
* Wilcoxon rank sum statistic for differences between groups 
 Change in Fasting Glucose, Insulin, and Insulin Sensitivity by Bergman FSIVGTT, 
and Serum Fructosamine Levels during the Year Long Study 
Throughout the study, fasting glucose values in conscious pigs did not 
change significantly (Table 2.5).  In contrast, when the pigs were sedated for the 
Bergman FSIVGTT, the glucose values were higher, possibly due to the stress of 
the procedure or the sedatives used (Table 2.6).[84, 85]  Fasting insulin values 
measured during the Bergman FSIVGTT were higher at 3 (p = 0.05) and 12 (p = 
0.01) months when compared to baseline values for the severe atherosclerosis 
group, whereas the moderate group showed little or no evidence of change (Table 
2.6). Fasting glucose during the Bergman FSIVGTT was significantly elevated at 12 
months compared to baseline in the severe group (p = 0.01) but had no evidence of 
change in the moderate group.  The mean Si values decreased significantly in all 
pigs at 6 and 12 months consistent with increased insulin resistance (p = 0.023 and 
0.004 for the severe atherosclerosis group, and p = 0.047 and 0.008 for the 
moderate atherosclerosis group compared to baseline, respectively). There was little 
or no evidence of differences in mean fasting glucose, insulin or Si values during the 
Bergman FSIVGTT between the severe and moderate atherosclerosis groups at any 
time point (Table 2.6, p > 0.05). With adjustments for baseline, such absence of 
differences for all time points had further confirmation from the repeated measures 
ANCOVA (p= 0.764 for fasting insulin, p= 0.616 for fasting glucose, and p= 0.351 for 
Bergman FSIVGTT, with each as logarithms). 
 
The serum fructosamine levels were similar at baseline for the moderate and 
severe groups (p=0.566).  They increased significantly at 3, 6, and 12 months 
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compared to baseline in the group that developed severe atherosclerosis (Table 2.7, 
p < 0.05).  There was no evidence of change in the group with moderate 
atherosclerosis.  Accordingly, the serum fructosamine level was significantly higher 
at 6 months in the severe group when compared to the moderate atherosclerosis 
group (p< 0.001); moreover, with adjustment for baseline, the repeated measures 
ANCOVA indicated that serum fructosamine levels for the severe group comparably 
exceeded those for the moderate group by an average of 0.227 mmol/L or ~15% at 
all post-baseline determinations (p<0.001, 95% CI (0.113, 0.340)). 
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 Table 2.5. Fasting Glucose in Conscious IR Pigs on the Year Long Study 
    
 
Severe 
Atherosclerosis 
(n = 9) 
 
Moderate 
Atherosclerosis 
(n = 9*) 
Fasting Glucose (mg/dl)    
Month:    1 75 ± 6  73 ± 8 
2 76 ± 6  73 ± 6 
4 77 ± 4  74 ± 9 
5 72 ±7  76 ± 13 
7 77 ± 7  72 ± 5 
8 76 ± 9  73 ± 11 
9 72 ± 5  79 ± 15 
10 74 ± 6  75 ± 11 
11 73 ± 4  76 ± 8 
    
*One pig was euthanized due to inappetance at 6 months, thus n = 8 for months 7 to 
12. 
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Table 2.6. Fasting Insulin and Fasting Glucose Values in IR Pigs While Sedated 
For Bergman Si Measurements during 12 Month Study 
      
  
Severe 
Atherosclerosis 
(n = 9) 
 
Moderate 
Atherosclerosis 
(n = 9†) 
 
Fasting Insulin 
(µU/ml)   p*  p* 
Baseline  10.0 ± 3.6  16.6 ± 12.3  
3 month  14.3 ± 6.6 0.05 16.0 ± 4.5 0.84 
6 month  15.6 ± 15.3 0.25 17.4 ± 9.0 0.82 
12 month  16.8 ± 7.1 0.01 17.9 ± 7.4 0.08 
      
Fasting Glucose 
(mg/dl)      
Baseline  102.6 ± 19.3  120.2 ± 24.0  
3 month  109.7 ± 38.2 0.82 112.7 ± 12.9 0.65 
6 month  115.0 ± 42.4 0.57 115.0 ± 38.4 0.91 
12 month  126.0 ± 29.5 0.01 119.0 ± 20.0 0.55 
      
Bergman Si      
Baseline  4.0 ± 0.5  3.8 ± 0.3  
3 month  3.8 ± 0.5 0.109 3.6 ± 0.4 0.063 
6 month  3.7 ± 0.6 0.023 3.5 ± 0.5 0.047 
12 month  3.4 ± 0.5 0.004 3.4 ± 0.3 0.008 
      
* Wilcoxon signed rank statistic for change from baseline within group. 
p>0.05, Wilcoxon rank sum statistic for differences between groups at all time points 
†One pig was euthanized due to inappetance at 6 months, thus n = 8 for month 12. 
 Table 2.7. Fasting Fructosamine Values in IR Pigs  
      
  
Severe 
Atherosclerosis 
(n = 9) 
 
Moderate 
Atherosclerosis 
(n = 9§) 
 
Fasting 
Fructosamine 
(mmol/L) 
  p*  p* 
Baseline  1.47 ± 0.17  1.45 ± 0.24  
3 month  1.77 ± 0.17‡ 0.004 1.61 ± 0.21‡ 0.07 
6 month  1.82 ± 0.14†‡ 0.004 1.45 ± 0.15†‡ 0.59 
12 month  1.60 ± 0.19‡ 0.027 1.43 ± 0.17‡ 0.74 
      
*Wilcoxon signed rank statistic for change from baseline within group 
† p<0.001, Wilcoxon rank sum statistic for differences between groups. 
‡ p<0.001, ANCOVA 
§ One pig was euthanized due to inappetance at 6 months, thus n = 8 at 12 months. 
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 Change in Weight, Backfat, and Blood Pressure during Year Long Study 
The baseline, 3, 6, and 12 month weight and backfat values and blood 
pressure values are shown in Tables 2.8 and 2.9, respectively. Weight increased 
significantly over time compared to baseline in the moderate atherosclerosis group 
(p < 0.05) and there were trends for increases in the severe group (p ≤ 0.10).  
Backfat increased significantly in both groups by 12 months (p < 0.05). There was no 
evidence of differences between the two groups for weight or backfat at study entry, 
nor at any of the time points (p ≥ 0.05). With adjustments for baseline, such absence 
of differences for all time points had further confirmation from the repeated 
measures ANCOVA (p= 0.316 for weight, p= 0.609 for backfat).   
Blood pressure was in a range that would be considered mildly hypertensive 
in humans with no evidence of differences between the two groups (Table 2.9). 
Blood pressure had little or no evidence for increase over time in either group except 
diastole at 12 months in the moderate group (p = 0.03). With adjustments for 
baseline, such absence of differences for all time points had further confirmation 
from the repeated measures ANCOVA (p=0.671 for systolic, p=0.659 for diastolic, 
p=0.728 for MAP, and p=0.506 for pulse). 
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Table 2.8. Weight and Backfat in IR Pigs on Year Long Study 
     
  Severe Atherosclerosis‡ Moderate Atherosclerosis‡ 
Weight (lb)   (n = 9)  (n = 9) 
Baseline  489 ± 66  491 ± 53 
3 month  527 ± 80*  536 ± 74† 
6 month  545 ± 79*  582 ± 71† 
12 month  594 ± 115*  643 ± 76† 
     
Backfat (cm)   (n = 7)  (n = 8) 
Baseline  8.1 ± 1.1  6.2 ± 2.1 
3 month  8.4 ±1.0  7.3 ± 1.4† 
6 month  9.0 ± 1.3  7.9 ± 0.9† 
12 month  9.6 ± 1.1†  8.9 ± 1.0† 
     
* p ≥ 0.05, Wilcoxon signed rank statistic for change from baseline within group 
† p ≤ 0.05, Wilcoxon signed rank statistic for change from baseline within group  
‡ p > 0.05, Wilcoxon rank sum statistic  for differences between groups 
Data are listed for pigs for which there was a complete 12 month data set except for 
one pig with moderate atherosclerosis that was euthanized at 6 months due to 
inappetance. 
 Table 2.9. Arterial Blood Pressure (mm Hg) in IR Pigs on the Year Long Study 
     
  
Severe  
Atherosclerosis 
(n = 7) 
 
Moderate  
Atherosclerosis 
(n = 8 ) 
Systolic     
Baseline  142 ± 27  135 ± 19 
3 month  147 ± 14  139 ± 20 
6 month  153 ± 28  148 ± 24 
12 month  146 ± 17  145 ± 23 
Diastolic     
Baseline  96 ± 21  83 ± 13 
3 month  96 ± 14  91 ± 20 
6 month  110 ± 32  98 ± 18 
12 month  103 ± 16  97 ± 22 
MAP*     
Baseline  113 ± 25  103 ± 15 
3 month  119 ± 15  114 ± 20 
6 month  127 ± 32  119 ± 22 
12 month  118 ± 18  115 ± 23 
Pulse     
Baseline  96 ± 16  94 ± 23 
3 month  105 ± 17  96 ± 17 
6 month  109 ± 9  94 ± 29 
12 month  93 ± 12  100 ± 17 
     
 
*MAP = mean arterial pressure 
p>0.05, Wilcoxon signed rank statistic for change from baseline at all time points for 
all values except diastole at 12 months for which p = 0.03 in the moderate 
atherosclerosis group. 
p≥0.09, Wilcoxon rank sum statistic for differences between groups at all time points  
Data are listed for pigs for which there was a complete 12 month data set except for 
one pig with moderate atherosclerosis that was euthanized at 6 months due to 
inappetance.
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 Total, LDL, and HDL Cholesterol and Triglyceride Levels  
Fasting total and LDL and HDL cholesterol and triglyceride values were 
similar for the moderate and severe groups at study entry (Table 2.10).  Fasting total 
and LDL and HDL cholesterol increased significantly at 3, 6, and 12 months relative 
to baseline values within groups (p< 0.05) but triglycerides had no evidence of 
change (p > 0.05). There was no evidence of differences between the moderate and 
severe groups at 3, 6, or 12 months (p ≥ 0.100). With adjustments for baseline, such 
absence of differences at all time points had further confirmation from the repeated 
measures ANCOVA (p= 0.153 for total cholesterol, p= 0.186 for LDL cholesterol, 
and p= 0.175 for HDL cholesterol, p = 0.194 for triglycerides, with each as 
logarithms). 
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Table 2.10. Fasting Total, LDL, and HDL Cholesterol and Triglycerides in IR 
Pigs on Year Long Study 
     
  Severe Atherosclerosis† 
(n = 9) 
Moderate 
Atherosclerosis† 
(n = 9 ‡) 
Total cholesterol (mg/dl)     
Baseline  82 ± 23  73 ± 12 
3 month  476 ± 177*  386 ± 113* 
6 month  422 ± 148*  305 ± 108* 
12 month  372 ± 66*  336 ± 76* 
LDL cholesterol (mg/dl)     
Baseline  45.0 ± 15.8  40.0 ± 11.3 
3 month  213.1± 68.9*  176.1 ± 49.6* 
6 month  184.8 ± 45.3*  144.4 ± 50.1* 
12 month  160.5 ± 27.1*  141.3 ± 24.2* 
HDL cholesterol (mg/dl)     
Baseline  32.5 ± 9.8  29.2 ± 6.0 
3 month  101.7 ± 31.1*  79.6 ± 27.6* 
6 month  82.7 ± 22.7*  79.7 ± 30.8* 
12 month  72.0 ± 23.4*  84.7 ± 15.8* 
     
Triglycerides (mg/dl)     
Baseline  24 ± 9  23 ± 7 
3 month  31 ± 13  24 ± 13 
6 month  31 ± 20  20 ± 15 
12 month  29 ± 12  22 ± 13 
*p<0.05, Wilcoxon signed rank statistic for change from baseline within group 
† p ≥0.10, Wilcoxon rank sum statistic for differences between groups  
‡ One pig in this group was euthanized due to inappetance at 6 months, thus n = 8 
for month 12. 
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Changes in Oxidized LDL  
The mean oxLDL levels were similar for the moderate and severe groups at 
baseline (p = 0.724, Table 2.11).  The values increased significantly relative to the 
baseline at 3, 6, and 12 months in both groups (p < 0.01).  OxLDL was significantly 
greater in the severe atherosclerosis group at 6 months (p = 0.008) and trends for 
increases at 12 months (p=0.061).  Moreover, with adjustment for baseline, the 
repeated measures ANCOVA (for logarithms) indicated that oxLDL levels for the 
severe group comparably exceeded those for the moderate group by an average of 
14.6% at all post-baseline determinations (p=0.025, 95% CI (1.9, 28.8)).  Thus, 
oxLDL was found to be more sensitive to differences in atherosclerosis between 
groups than LDL cholesterol, but an independent effect beyond that of total LDL 
could not be identified. 
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Table 2.11. oxLDL Levels (units/L) in IR Pigs on Year Long Study 
      
  
Severe 
Atherosclerosis 
(n = 9)  
Moderate 
Atherosclerosis  
(n = 9§)   
 
p† 
oxLDL (units/L)      
Baseline  21.74 ± 2.42 21.19 ± 2.43  0.724 
3 month  32.59 ± 5.44*‡ 31.46 ± 7.02*‡  0.596 
6 month  35.75 ± 6.33*‡ 27.91 ± 5.20*‡  0.008 
12 month  35.61 ± 4.37*‡ 30.34 ± 6.39*‡  0.061 
      
*p≤0.01, Wilcoxon signed rank statistic for change from baseline within group 
† Wilcoxon rank sum statistic for differences between groups 
‡p = 0.025, ANCOVA 
§One pig was euthanized due to inappetance at 6 months thus n = 8 at 12  months. 
 Changes in Aldosterone  
The mean aldosterone levels were similar for the moderate and severe 
groups at baseline (p=0.48, Table 2.12).  The values did not increase in the group 
with moderate atherosclerosis whereas with severe disease there was a highly 
significant increase above baseline values.  With adjustment for baseline, the 
repeated measures ANCOVA (for logarithms) indicated that aldosterone levels for 
pigs that developed severe atherosclerosis comparably exceeded those for pigs with 
moderate atherosclerosis by an average of 47.4% at all post-baseline 
determinations (p=0.023, 95% CI (6.0, 105.1)).  Serum potassium and sodium levels 
were assayed monthly and remained within the normal range (not shown). 
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Table 2.12. Fasting Aldosterone Values in IR Pigs  
     
  
Severe 
Atherosclerosis  
(n = 9) 
 
Moderate 
Atherosclerosis  
(n = 9 ‡)  
Aldosterone (pg/ml)     
Baseline  149.9 ± 109.1  176.2 ± 117.4 
3 month  170.2 ± 96.7*†  148.8 ± 90.0† 
6 month  177.7 ± 77.1*†  131.2 ± 64.3† 
12 month  212.2 ± 66.6*†  155.0 ± 87.0† 
     
*p<0.05 for increase from baseline (ANCOVA) 
† p = 0.023, ANCOVA 
‡One pig in this group was euthanized due to inappetance at 6 months, thus n = 8 
for month 12. 
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Change in Inflammatory Markers during Year Long Study 
The inflammatory markers had no evidence of differences between the 
moderate and severe groups when the mean values are compared at all time points 
during the 12 month study (Table 2.13, p > 0.05).  The inflammatory marker TNF-
alpha was significantly increased from baseline in the severe atherosclerosis group 
at 3 and 12 months (p < 0.05). IL-6 had no evidence of change within either group.  
PAI-1 increased significantly in both groups at 3 months and in the moderate 
atherosclerosis group at 6 months (p < 0.05).  CRP increased significantly in the 
group that developed moderate atherosclerosis at 3 months (p < 0.05) and exhibited 
a trend at 12 months (p = 0.06). With adjustments for baseline, the absence of 
differences between the moderate and severe groups for the inflammatory markers 
at all time points had further confirmation from the repeated measures ANCOVA 
(p=0.138 for TNF-alpha, p=0.411 for IL-6, p= 0.288 for PAI-1, and p= 0.846 for CRP, 
with each as logarithms). 
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Table 2.13. Inflammatory Markers in IR Pigs on Year Long Study 
     
  
Severe 
Atherosclerosis  
(n = 9) 
 
Moderate 
Atherosclerosis  
(n = 9 †)  
TNF-alpha (pg/ml)     
Baseline  24.2 ± 35.2  32.8 ± 29.9 
3 month  84.9 ± 88.6*  66.0 ± 84.8 
6 month  35.0 ± 38.1  50.3 ± 43.0 
12 month  96.5 ± 119.7*  50.1 ± 52.8 
     
IL-6 (pg/ml)     
Baseline  31.0 ± 92.9  10.0 ± 15.4 
3 month  20.9 ± 56.5  37.4 ± 42.3 
6 month  37.2 ± 73.9  ND 
12 month  35.3 ± 62.3  16.0 ± 29.7 
     
PAI-1 (ng/ml)     
Baseline  3.7 ± 4.1  2.2 ± 3.9 
3 month  9.2 ± 8.1*  7.0 ± 4.3* 
6 month  3.7 ± 3.0  4.0 ± 4.7* 
12 month  1.5 ± 1.3  2.9 ± 5.3 
     
CRP (µg/ml)     
Baseline  10.7 ± 11.5  4.3 ± 2.3 
3 month  10.0 ± 9.4  14.4 ± 19.8* 
6 month  10.9 ± 7.2  8.2 ± 9.7 
12 month  13.5 ± 14.3  7.7 ± 3.6 
ND = not detected  
p>0.05, Wilcoxon rank sum statistic for differences between groups at all time points 
for all markers. 
*p ≤ 0.05, Wilcoxon signed rank statistic when compared to baseline within group. 
†One pig was euthanized due to inappetance at 6 months, thus n=8 for month 12.
 Discussion 
 The study shows that 18 adult pigs fed a high fat diet with increased NaCl 
exhibited a significant increase in IR that was accompanied by comparable weight 
gain, increased backfat, elevation in total and LDL and HDL cholesterol levels, blood 
pressure, and inflammatory markers. Those pigs that exhibited more severe as well 
as diffuse distal coronary artery and proximal abdominal aortic atherosclerosis had 
significant increases in fructosamine and aldosterone levels during the study. Both 
groups had significant increases in oxLDL but the degree of increase was 
significantly greater in the group of animals with severe and diffuse disease. 
Although all animals developed increased IR during the study, the severity of IR did 
not correlate with the severity of atherosclerosis.  Since none of the IR pigs had 
diabetes, it appears that severe and diffuse atherosclerosis can develop in response 
to a high fat/high NaCl diet in the absence of overt hyperglycemia but in association 
with increased oxLDL, fructosamine, and aldosterone levels consistent with 
increased oxidative stress. These findings suggest that this degree of IR is not 
sufficient by itself to increase atherosclerosis severity in this model. Definitive proof 
of a single mechanism that predisposes to severe atherosclerosis among these 
parameters, the determination of whether or not these parameters are additive or 
synergistic, or the establishment of a hierarchy among them is beyond the scope of 
this work.  
 
 
Insulin Resistance 
 Although fully manifested diabetes mellitus confers a greater risk for 
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cardiovascular disease and other complications as compared to isolated IR without 
hyperglycemia, the presence of IR is a major independent risk factor with relative 
risk ratios between 2.2 and 2.7 when multifactorial linear regression analysis is 
utilized to assess risk.[25, 86, 87] Thus, both IR and hyperglycemia appear to 
independently confer additional vascular disease risk. The manner in which the 
hyperinsulinemic state or the loss of insulin sensitivity leads to increased 
atherosclerosis remains poorly defined.  In addition to increased oxidative stress, 
changes in markers of vascular inflammation that are related to changes in fat mass, 
changes in lipoprotein metabolism, and altered sensitivity of vascular cell types to 
other hormones such as angiotensin II have been proposed as mechanisms. 
Additionally the presence of IR is associated with hypertension, lipoprotein 
abnormalities, and chronic kidney disease that further accentuate atherosclerosis 
risk.[88-93]  
Our IR pigs had elevated glucose levels during the Bergman FSIVGTT when 
sedated but not when fully conscious (Tables 2.5 and 2.6).  It is possible that the 
sedatives used in these pigs contributed to the glucose elevations. Isoflurane has 
been shown to alter insulin sensitivity in pigs, possibly from direct drug effects as 
well as procedure-related stress.[84, 85]  Importantly, since all Si measurements 
were done with sedation and indicate a significant reduction in Si, the reduction over 
12 months is interpretable and was clearly progressive. In addition, studies have 
shown that stress induced hyperglycemia correlates with subsequent development 
of diabetes and that the subjects who were predisposed to develop glucose 
intolerance during the FSIVGTT had higher fructosamine levels at baseline (see 
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discussion on fructosamine below).[94]  It is noteworthy that a group of insulin 
sensitive pigs (n = 6) fed regular pig chow in other studies exhibited a range of mean 
Si values from 4.5 ± 0.6 to 4.8±0.6 and range of mean glucose values of 75.4± 4.5 to 
88 ± 13 mg/dl measured on samples drawn using the same sedation protocol (data 
not shown).  Therefore, it is probable that feeding the high fat/high NaCl diet induced 
some degree of glucose intolerance that was detectible during stress.  
 
Fructosamine 
Fructosamine is used as an index of mean blood glucose in pigs since pig red 
blood cells are relatively impermeable to glucose and thus hemoglobin A1c is not a 
reliable index of mean glucose concentrations.[95]  In our study, the fructosamine 
levels measured during the fasting state rose relative to baseline values in the group 
of animals that developed severe and diffuse disease but the levels were not 
elevated to a point that they would reflect significant and/or sustained 
hyperglycemia.  
Fructosamine has also been shown to correlate with 2 hr postprandial 
glucose[96] and relatively short periods of hyperglycemia have been shown to 
increase protein glycation even if fasting glucose is not increased.[97]  In general 
most reports have compared the degree of fructosamine change that occurs with 
impaired glucose tolerance to subjects with normal glucose tolerance and correlated 
this with a change in atherosclerotic risk.  Studies in experimental animal models 
have reported increases in fructosamine over the range noted in our animals as 
being associated with biochemical changes that are believed to predispose to 
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increase risk of atherosclerosis and some studies have demonstrated an increase in 
lesion formation.[98]  However, studies in which fructosamine changes alone 
predispose to increased risk have not been reported. Presumably the increase in 
fructosamine in the group of pigs with severe atherosclerosis reflects modest 
increase in mean daily glucose levels, although periods of post prandial 
hyperglycemia of short duration cannot be excluded. Regardless of the cause, the 
degree of increase was significantly greater than the change that occurred in the 
group with moderate atherosclerosis. Therefore, it is possible that even this modest 
change (0.227 mmol/L or ~15%) in fructosamine reflects a contribution of increased 
mean glucose values to increased oxidative stress and on lesion development. 
 
oxLDL 
Increases in oxidized LDL in humans, pigs, and rodents correlate with 
increased atherosclerosis and reduction in oxLDL correlates with reduced 
atherosclerosis.[96, 99-104]  In our study, the increase in oxLDL was probably due 
in part to increases in total cholesterol in both groups although increases in glycated 
proteins as reflected by fructosamine in the group with severe atherosclerosis may 
have contributed to the greater degree of increase in oxLDL in that group.  The 
animals with increased fructosamine had greater increases in oxidized LDL 
compared to total LDL suggesting that the change in fructosamine may have been a 
significant component of the change in oxLDL, thus leading to a more severe 
atherosclerosis phenotype. 
In humans increased glycemic index correlates with increased oxLDL when 
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total LDL remains unchanged.[99, 105-107]  Also, reductions in fat mass, dietary fat, 
and blood glucose have been shown to be associated with decreases in 
oxLDL.[108-111]  More modest increases in postprandial glucoses in subjects with 
impaired glucose tolerance can also lead to increases in oxLDL[112-115] and 
treatment in those subjects also lowers oxLDL.[116-119]  A few studies have 
reported increases in oxLDL in nondiabetic subjects with impaired glucose 
tolerance[120-122] and one reported a correlation between oxLDL in normal 
subjects with higher fructosamine.[120]  Moreover, even small increases in 
postprandial glucose that are within the normal range can lead to increases in 
oxidized LDL[99, 123] and small reductions in postprandial glucose in patients with 
type 2 diabetes also lead to decreased oxidized LDL.[99, 123]  Since oxidized LDL 
was increased in our animals with severe atherosclerosis, it is possible that 
increases in their postprandial glucoses were sufficient to contribute to the increased 
LDL oxidation to levels that were greater than the group of animals that tended to 
have slight or no changes in fructosamine.  
 
Aldosterone 
The significant increase in aldosterone in pigs with severe atherosclerosis is 
consistent with the suspected role of the renin-angiotensin-aldosterone system 
(RAAS) in insulin resistance, oxidative stress, and severity of atherogenesis.[124]  
Activation of the RAAS system has been associated with increased reactive oxygen 
species formation.  In statistical models that controlled for oxLDL or fructosamine 
and baseline levels (i.e., change over time), gender, and atherosclerosis severity, 
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pigs with severe atherosclerosis had significantly higher aldosterone levels (p<0.05, 
ANCOVA).  This result suggests that the increased aldosterone levels may have 
contributed to the increased oxLDL in the pigs with severe atherosclerosis.  Also, 
pigs with increased aldosterone levels did not have higher blood pressure than those 
with lower aldosterone levels. While this finding seems counterintuitive, the 
experimental cholesterol ester transfer protein (CETP) inhibitor torcetrapib increased 
aldosterone levels by a mechanism that did not explain the pressor effect of the 
drug.[125, 126]  Thus, significant elevations in aldosterone do not predictably 
increase blood pressure but can still contribute to increases in oxidative stress.     
 
Inflammatory Markers 
 TNF-alpha, IL-6, PAI-1, and CRP were not significantly different between 
groups.  In some cases, these values were significantly increased over baseline 
values but this was an inconsistent finding.  Thus, these values do not appear to be 
robust markers of IR or atherosclerosis in this model. 
 
Atherosclerosis Morphology in Insulin Resistance 
 Coronary artery atherosclerosis in the IR pigs showed fibrous cap formation, 
foam cells, medial thinning, plaque hemorrhage, necrosis, and calcification (Figure 
2.2).  All of these characteristics have been described in atherosclerotic plaques 
from IR and diabetic humans.[28, 30]  Similar histological findings have been 
described in pigs given streptozotocin and fed a high fat diet.[49]  An important 
characteristic is the presence of distal coronary atherosclerosis which has been a 
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consistent finding in asymptomatic IR and diabetic patients screened by electron 
beam computed tomography and magnetic resonance imaging,[27, 31] clinically 
symptomatic IR patients by quantitative angiography[29] and in type 2 diabetic 
patients who died suddenly.[28]  Thick fibrous caps (>64 µm) are more common in 
coronary atherosclerotic plaques of humans with type 2 diabetes that died 
suddenly.[28]  In our study, the fibrous caps were more abundant in pigs with severe 
atherosclerosis than those with moderate atherosclerosis. Clinical studies have 
reported an increase in remodeling in diabetic victims of sudden death.[28]  The 
mean total IEL areas for serial sections in all 3 coronary arteries from IR pigs with 
severe atherosclerosis was larger than those with moderate atherosclerosis (Table 
2.2).  This finding is consistent with positive remodeling.[28, 82, 83]  Thus, the 
atherosclerotic plaques in these IR pigs with severe disease exhibit several of the 
phenotypic characteristics that are found in IR humans.  
 
Study Limitations 
First, our study does not include an insulin sensitive control. This means we 
do not know how much atherosclerosis would develop in insulin sensitive pigs with a 
comparable degree and duration of hypercholesterolemia.  Second, we do not know 
how much atherosclerosis would develop in insulin resistant pigs fed a low fat diet.  
However since the absolute level of insulin resistance was comparable in our two 
groups of animals, this parameter did not appear to account for the differences in 
disease severity. Nonetheless, it is probable that reducing insulin sensitivity 
contributed to the development of atherosclerosis that occurred in both groups of 
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animals. Third, we chose to measure parameters that have been associated with 
increased atherosclerosis severity in insulin resistant humans: blood pressure, body 
weight, body fat, hyperlipidemia, inflammatory markers, glycated proteins (i.e., 
fructosamine), oxLDL, and aldosterone. This study design addressed the extent to 
which each of these parameters, when measured at 4 time points, were associated 
with the severity of atherosclerosis that developed in pigs with comparable IR. The 
grouping of pigs by atherosclerosis severity was only possible after feeding the high 
fat diet for one year.  Likewise, evaluating these parameters for association with 
atherosclerosis severity could only be done after the groups were identified. This 
post hoc grouping and analysis could be viewed as possibly introducing bias, 
although it is comparable to a ranking of the pigs as in a rank correlation statistical 
test. We have additionally addressed this possibility by analyzing changes over time 
with appropriate and validated statistical methods.[127]  We may have inadvertently 
omitted other parameters that could be associated with atherosclerosis severity that 
could also be analyzed in a similar fashion.  
 
Summary 
 Our goal was to develop a useful animal model of insulin resistance that also 
develops coronary and aortic atherosclerosis. Several investigators have used pigs 
to study the impact of diabetes on atherogenesis, most of which have used chemical 
induction of insulin-deficiency.[23, 48, 49, 128]  In contrast, we used pigs that 
developed increased insulin resistance in association with weight gain, increasing 
backfat, increased total and LDL and HDL cholesterol levels, and comparable blood 
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pressure and changes in inflammatory markers.  Our model has some features of 
the metabolic syndrome and a subgroup of animals developed more severe and 
diffuse atherosclerosis.  The metabolic variables that predict this increase in disease 
severity are increases in fructosamine, oxidized LDL, and aldosterone.  If these 
findings can be confirmed and the degree of glucose abnormality that is required to 
develop these changes be determined, then these animals should be useful for 
studying mechanisms of disease and for testing new therapeutic approaches. 
 Chapter 3 
Gene Expression Profiles of Aortic Endothelium in Hyperlipidemic, 
Hyperinsulinemic Swine 
 
Abstract 
 
We have previously shown that fifty percent of adult insulin resistant pigs fed 
a high fat diet containing high NaCl developed severe and diffuse distal coronary 
atherosclerosis and severe and diffuse proximal abdominal aortic atherosclerosis. 
These pigs also had significantly higher oxLDL and greater increases in 
fructosamine and aldosterone values consistent with increased oxidative stress than 
the fifty percent with moderate atherosclerotic disease.  Endothelial dysfunction is an 
early and critical step in atherosclerosis.  OxLDL is known to cause changes in 
endothelial cells that alter endothelial barrier function.  In the current study, we use 
gene expression profiles from normal and atherosclerotic endothelium of both the 
severe and moderate disease groups to identify potential molecular targets involved 
in oxidative stress (pathway for increased oxLDL), protein glycation, and/or the 
renin-angiotensin-aldosterone system.  We identified three genes (MERP-1, 
RABGAP1L, and COL12A1) that were uniquely expressed in atherosclerotic 
endothelium of the severe group and one gene (SERPINI1) that was uniquely 
expressed in normal endothelium of the severe group.  Overall comparison of the 
severe disease group to the moderate disease group identified genes involved in cell 
 
 
adhesion, migration, and proliferation or transcription and translation that were either 
significantly up- (PTPRM, FAM5C, CLOCK, MYCPBP, LPHN2, HIPK2) or down 
(TMSB4X, EIF2S3, JARID1C) -regulated in the severe disease group.  This study 
identifies potentially important genes for further investigation of the endothelial 
dysfunction seen in these pigs. 
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Introduction 
Normal, healthy endothelium has numerous beneficial effects, including: 
promotion of vasodilation; antioxidant, anti-inflammatory, anticoagulant, and 
profibrinolytic effects; and inhibition of leukocyte adhesion and migration, smooth 
muscle cell proliferation and migration, and platelet aggregation and adhesion.[8]  
Endothelial dysfunction, while an early and potentially reversible step, can lead to 
the initiation and progression of atherosclerosis.  
The progression of endothelium from normal to dysfunctional to 
atherosclerotic may parallel the progression of insulin resistance to overt 
diabetes.[10]  Studies have shown that insulin resistance co-associates with other 
factors that lead to endothelial dysfunction, especially changes in lipoproteins.[11]  
Insulin works through both the phosphatidylinositol 3-kinase pathway to regulate 
endothelial nitric oxide (NO) production and as a growth factor through the mitogen 
activated protein kinase (MAPK) pathway to affect cell growth and movement, 
increase endothelial cell (EC) adhesion markers and mediate expression of certain 
prothrombotic factors.[11]  Pathologic changes, such as increases in oxLDL and 
subsequent expression of TNF-α by macrophages, can lead to changes in 
endothelial gene expression.  An initial change is an increase in leukocyte adhesion 
molecules on the surface of ECs. Other changes include an increase in inducible 
nitric oxide synthase and a decrease or suppression of endothelial nitric oxide 
synthase.  Changes in gene expression continue as the underlying lesion 
progresses. 
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 A study of changes in aortic EC gene expression from streptozotocin induced 
type-1 diabetic rats showed a significant number of up and down-regulated genes.  
Insulin treatment in these rats normalized about half of the genes, suggesting that 
levels of both glucose and insulin are important in EC gene expression and 
subsequent development of diabetic cardiovascular complications.[129] Likewise, 
studies of cultured human aortic endothelial cells subjected to high glucose had 
increases in eNOS gene expression.[130] 
Novel insight into the molecular mechanisms underlying endothelial 
dysfunction and hence initiation and progression of atherosclerosis may be possible 
through gene expression studies.  Seo et al used human aorta samples with varying 
degrees of atherosclerosis to establish gene expression profiles.  Using the list of 
genes generated, they were able to predict disease burden and potential 
susceptibility to atherosclerosis related to anatomic location.[131]  However, this 
study utilized RNA extracted from whole aortic tissue and may not be reflective of 
specific changes in the endothelium. 
A recent study by our group looked at atherosclerosis severity in adult insulin 
resistant pigs (n=18) fed a high fat diet that also contained high NaCl (56% above 
recommended levels) for 1 year. Fifty percent of the pigs in this study developed 
severe and diffuse distal coronary atherosclerosis and severe and diffuse proximal 
abdominal aortic atherosclerosis. The other fifty percent had moderate 
atherosclerosis. There were comparable elevations in total and LDL and HDL 
cholesterol, weight gain, increase in backfat, blood pressure, and inflammatory 
markers, and increase in insulin resistance without overt diabetes between both 
 57
groups. There was no correlation between insulin resistance and the severity of 
atherosclerosis. Nonetheless, the pigs with severe atherosclerosis had significantly 
higher oxLDL and greater increases in fructosamine and aldosterone values 
consistent with increased oxidative stress than the pigs with moderate 
atherosclerosis.  
  In this paper, we used endothelium from both normal and atherosclerotic 
aortic of both groups of pigs (severe and moderate disease) in the previous study.  
Through microarray technology we identified both up and down-regulation of 
endothelial cell genes based on the severity of atherosclerosis or state of the 
endothelium. This approach should provide some insight into the patterns of gene 
expression, potentially from atherosclerosis initiation through progression to 
advanced disease.  Special attention was paid to identifying genes that may be 
involved in endothelial dysfunction relating specifically to oxidative stress (pathway 
for increased oxLDL), protein glycation, and/or the renin-angiotensin-aldosterone 
system. Our long range goal is to develop novel methods for the noninvasive 
detection of endothelial dysfunction that occurs during atherogenesis in a relevant 
animal model. 
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Methods 
 
Experimental Pigs 
All pigs were treated according to the standards set in the Guide for Care and 
Use of Laboratory Animals (National Institutes of Health publication No. 85-23).  All 
procedures and protocols were in accordance with institutional guidelines and 
approved by the Institutional Animal Care and Use Committee.  All pigs were 
produced and maintained in the same environmental conditions at the Francis Owen 
Blood Research Laboratory at the University of North Carolina at Chapel Hill.   Male 
and female pigs were from Spotted Poland/China and Yorkshire crosses. At study 
termination all pigs were euthanized with an overdose of pentobarbital (6 grains/ 10 
lbs. IV).  
 
Study design   
Eighteen pigs were entered into the year-long study (11 males, 7 females).  
Aortic endothelium was only available from 10 pigs (6 males, 4 females); average 
age at start of study was 4.4 ± 2.1 years.    Pigs from the following two genotypes 
were used: normocholesterolemic (n=7), and heterozygous familial 
hypercholesterolemic (FH) which are also normocholesterolemic at baseline (n=3).  
Neither normocholesterolemic nor heterozygous familial hypercholesterolemic pigs 
exhibit hypercholesterolemia unless they are fed a high fat diet.  The animals were 
fed a high fat diet that consisted of pig chow (5NP8 Wayne™ 15% Pig & Sow 
Pellets, Granville Milling, Granville NC) supplemented with 1% cholesterol, 20% beef 
tallow, and 0.75% cholate by weight.  The aortas of the pigs were collected at 
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euthanasia and placed on ice to minimize postmortem changes.   Endothelium was 
collected from both normal and atherosclerotic abdominal aorta.  Disease burden 
was segregated into two phenotypes, severe and moderate.  Severe abdominal 
aortic atherosclerosis was defined as >50% of abdominal aorta with raised 
atherosclerosis lesions.   By collecting both normal and atherosclerotic aortic 
endothelium from the same pig, a matched set of samples was then available for 
analysis. 
Other variables were measured at baseline, 3, 6, and 12 months and 
included:  weight, backfat, blood pressure, insulin sensitivity, fructosamine, total and 
LDL and HDL cholesterol, triglycerides, oxidized LDL, inflammatory makers, and 
aldosterone.  For detailed methods used to measure each of these variables, see 
Chapter 1 – Methods section. 
 
Endothelial Cell Isolation   
RNase-free techniques, reagents, materials, and tools were used during all 
procedures. Porcine aortas were obtained from necropsy, and all endothelial cell 
isolations were performed immediately after necropsy on fresh tissue to minimize 
transcriptional changes and RNA degradation. Aortic endothelial RNA isolation was  
based on a method by Simmons et al[132], as follows.  Immediately after necropsy, 
aortas were rinsed with diethyl pyrocarbonate (DEPC)-treated phosphate buffered 
saline (PBS).  Aortas were then cut longitudinally, spread on a cutting surface with 
the orientation of the aorta luminal surface side up.  A 12-mm #1 glass coverslip was 
dipped into isopentane on dry ice, blotted to remove excess isopentane and carefully 
 60
placed on the luminal surface so as to be in contact only with endothelial cells. The 
coverslip was pressed firmly with a cold aluminum rod (stored in isopentane on dry 
ice between uses) for 5-10 seconds (See Figure 3.1), which froze the endothelial 
layers to the glass coverslips.  The circular surface area of the aluminum rod on the 
“pressed” end ensured wide contact of the endothelium with the coverslip. The 
coverslips with endothelial cells frozen to them were then gently peeled off and 
immediately placed/covered in lysis buffer for RNA extraction or in 4% 
paraformaldehyde for immunostaining.  This procedure was repeated several times 
on each aorta and covered both raised lesions (atherosclerotic) and “normal” (non-
atherosclerotic) aortic surfaces.   
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Figure 3.1.  Endothelial cell isolation via frozen coverslip technique. 
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Immunohistochemistry 
Coverslips with frozen cells were fixed in 4% paraformaldehyde for 5 min at 
room temperature.  After fixation, the slides were rinsed in PBS for 5 min and then 
permeabilized with a solution of 0.3% Triton-X and 0.1% Tween-20 in PBS for 15 
min at room temperature. Following a 5-min PBS wash, nonspecific primary antibody 
binding was blocked with 10% normal goat serum (NGS) for 30 min at 37°C. After 
blocking, the slides were incubated overnight at 4°C with the following antibodies: 
rabbit anti-human von Willebrand Factor (vWF, 1:250 dilution in 10% NGS; Dako 
Cytomation, Carpinteria, CA); mouse anti-human α-smooth muscle actin (α-SMA, 
1:250 dilution in 5% goat serum; Sigma).   A no-primary control for one slide for each 
antibody was incubated with 5% NGS instead of the primary antibody.  Following 
overnight incubation, the coverslips were washed 3 × 10 min in PBS, and 
nonspecific secondary antibody binding was blocked by incubating the slides in 10% 
NGS at 37°C for 30 min.  Secondary antibody staining was at room temperature for 
1 hour, with Alexa-fluor 594 goat anti-rabbit and Alexa-fluor 488 goat anti-mouse 
(1:500 dilution in blocking buffer; Invitrogen).  The coverslips were washed 3 × 10 
min in PBS and placed on a microscope slide with 5 μl of a medium containing DAPI 
(Invitrogen, Carlsbad, CA).  The cells were observed on a Zeiss microscope, and 
images were acquired using a CCD camera (Jenoptik, Jupiter, FL) and processed 
using CCD camera software (Jenoptik, Jupiter, FL). 
 
RNA Isolation and Amplification 
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Total RNA was isolated using the Absolutely RNA Nanoprep Kit (Stratagene, 
Cedar Creek, TX) according to the manufacturer’s instructions. Briefly, coverslips 
with attached frozen endothelium were quickly placed endothelium side up into 
guanidine thiocyanate (GITC) lysis buffer (Absolutely RNA Nanoprep Kit, 
Stratagene). The coverslips were scraped vigorously with sterile disposable cell 
scrapers, and the cell lysate was collected in microfuge tubes, vortexed and frozen 
at -80°C for future processing.  For processing, cell lysates were thawed and mixed 
with an equal volume of 70% ethanol, and loaded onto spin columns which 
contained a silica-based fiber matrix that binds RNA during centrifugation 
(Absolutely RNA Nanoprep Kit, Stratagene).  Any DNA contamination was digested 
on the column matrix by adding a DNase I treatment at 37◦C.  DNases and other 
contaminants were removed by a series of washes in low and high salt buffers.  The 
remaining purified RNA was eluted from the fiber matrix by using RNase-free dH20. 
The resulting RNA solution was concentrated by vacuum centrifugation. Total RNA 
quantity and integrity were evaluated using an Agilent Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA), a microfluidics-based platform that permits 
electrophoretic separation of picogram quantities of fluorescently-labeled RNA, 
allowing measurements of RNA quantity and quality. Total RNA samples and RNA 
standards (RNA 6000 Ladder, Ambion, Inc., Austin, TX), were prepared and 
processed according to the manufacturer’s protocol. Using Agilent Bio-Sizing 
software, ribosomal RNA fragments of 28S and 18S and their concentrations were 
automatically detected on the RNA electropherogram. Total RNA was judged to be 
intact if the ribosomal fragments were present in a 28S:18S ratio of 2:1 and scored 
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using an RIN assessment numbering system.  10-100ng of total RNA was extracted 
for all samples.  Affymetrix 2 cycle IVT kit was used to generate cRNA probes 
according to the manufacturer’s instructions. 
 
Microarray Analysis  
Amplified RNAs were hybridized to the Porcine GeneChip (Affymetrix, Santa 
Clara, CA), which interrogates 23,256 transcripts that represent 20,201 genes.  The 
expression intensities for all genes across the samples were normalized using the 
robust multi-array average (RMA), including probe-level quantile normalization and 
background correction.  Based on quality control metrics, 4 arrays from two pigs 
were removed from the dataset due to poor Affymetrix chip hybridizations as seen 
by Affymetrix’s QC metrics analysis.  All four samples had high scaling factors and 
low signal intensities outside the acceptable boundaries.  These four RNA 
preparations may have entered the RNA amplification steps with poorly degraded or 
too low abundant total starting RNA.  We will exclude these 4 samples from further 
analysis.   
Data analysis was performed using Partek Genomics Suite Version 6.4 
(Partek, St. Louis, MO).  A principal component analysis (PCA) was modeled to 
assess the global analysis of the array data in order to identify major effects 
influencing expression values in this experiment.  PCA mapping of the samples 
provides a multidimensional gene space that helps visualize gene expression trends.  
In particular it is also useful analysis in identifying outliers, which could be indicative 
of poor quality RNA, flawed hybridizations, or experimental batch effects. 
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Analysis of variance (ANOVA) of the microarray data was performed on the 
dataset of 16 arrays using Partek software to partition variance due to RNA 
isolation/preparation of sample, gender, age, and disease burden in order to 
determine which genes were significantly up or down regulated in the 
severe/moderate lesions vs. matched non-atherosclerotic tissue, and in the 
comparison of severe versus moderate lesions.  A false discovery rate (FDR) of q<0.05 
was used as a significance threshold.  Partek uses FDR for multiple test correction using the 
step up[133], step down[134], and q-Value[135] methodology. 
  
Statistical Analysis  
Descriptive statistics for weight, backfat, blood pressure, triglycerides, total 
and LDL cholesterol, oxLDL, fructosamine, inflammatory markers, insulin, glucose, 
Bergman Si values, coronary and aortic atherosclerosis measurements are reported 
for all groups as means ± SD.  In the original study, the Wilcoxon signed rank test 
was used to assess within group change and for pair-wise comparisons of conditions 
within groups.  The Wilcoxon rank sum test was used for comparisons between two 
groups.  A p value of < 0.05 was considered significant. 
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Results  
While eighteen pigs were entered into the year-long study, both normal and 
atherosclerotic aortic endothelium was only available from ten pigs.   Based on 
quality control metrics, endothelial RNA from two of the remaining pigs was removed 
from the dataset due to poor Affymetrix chip hybridizations and has been excluded 
from further analysis. 
 
Severity of Atherosclerosis   
The eight remaining pigs were segregated into two groups based on the 
amount of aortic atherosclerosis. Severe abdominal aortic atherosclerosis was 
defined as having >50% of abdominal aorta with raised atherosclerosis lesions and 
moderate abdominal aortic atherosclerosis was defined as having <50% of 
abdominal aorta with raised atherosclerosis lesions. Atherosclerosis morphometry 
measurements are shown in Table 3.1 for both aorta and coronary arteries.  While 
the abdominal aortic surface area and medial areas did not vary significantly 
between groups, the severe group had significantly greater area with raised lesion, 
percent aortic area with raised lesions, intimal area, and intimal area as percent of 
medial area than the moderate group.  Similar results were seen when comparing 
coronary arteries.  (Results for coronary artery morphometry are shown in Table 3.1 
for completeness and comparison.)  Differences between the groups for the distal 
half of the abdominal aorta tended to be absent or less evident than those for the 
proximal half. Distinctions between proximal and distal are important as abdominal 
aortic atherosclerosis in swine and humans begins at the aortoiliac junction and 
progresses in a retrograde fashion.[77-81]  
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Table 3.1.  Atherosclerosis Morphometry in IR Pigs 
     
  Moderate  Severe 
  (n=4)  (n=4) 
Abdominal aorta:     
Total aortic surface area (cm2)  34.0 ± 6.5  29.8 ± 5.2 
Area with raised lesion (cm2)*  11.5 ± 3.4  20.2 ± 5.3 
% aortic surface with raised lesions*  33.4 ± 6.6  66.8 ± 7.9 
Medial area (mm2)  37.9 ± 11.4  31.4 ± 7.2 
Intimal area (mm2)*  2.4 ± 1.6  6.0 ± 2.1 
Intimal area as % medial area*  5.9 ± 2.7  19.3 ± 8.0 
     
Proximal Half Abdominal Aorta:   
Total aortic surface area (cm2)  16.8 ± 2.5  15.1 ± 3.4 
Area with raised lesion (cm2)*  3.2 ± 0.9  9.5 ± 2.9 
% aortic surface with raised lesions*  19.5 ± 7.6  62.0 ± 7.0 
Medial area (mm2)  38.7 ± 10.3  29.3 ± 7.3 
Intimal area (mm2)*  1.2 ± 0.3  5.5 ± 2.2 
Intimal area as % medial area*  3.4 ± 1.6  18.1 ± 6.2 
     
Distal Half Abdominal Aorta:     
Total aortic surface area (cm2)  17.2 ± 4.2  14.7 ± 2.0 
Area with raised lesion (cm2)  8.3 ± 3.3  10.7 ± 2.5 
% aortic surface with raised lesions*  47.3 ± 12.6  71.7 ± 9.4 
Medial area (mm2)  37.3 ± 14.1  33.2 ± 9.8 
Intimal area (mm2)  3.7 ± 3.5  6.6 ± 2.0 
Intimal area as % medial area  8.7 ± 5.4  20.7 ± 9.9 
     
Coronary arteries:     
Medial area (mm2)  6.7 ± 0.9  5.3 ± 1.2 
Intimal area (mm2)*  2.4 ± 0.7  7.1 ± 2.2 
% Stenosis*  42.7 ± 13.2  73.9 ± 7.5 
Intimal area as % medial area*  46.8 ± 20.3  180.7 ± 64.8 
     
*p<0.04 between groups 
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Demographic and Metabolic Characterization 
Demographic and metabolic data at the start and end of the study are shown 
in Table 3.2.  There were no significant differences between groups at start or end 
for age, weight, backfat, fasting insulin, fasting glucose, triglycerides, blood 
pressure, aldosterone, or inflammatory markers.  Slight differences are seen from 
the original study due to the drop (n=8 vs. n=18) in animal numbers. 
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Table 3.2. Pig Demographic and Metabolic Characterization at Start and End of 12 
Months of Study 
 Moderate (n=4)  Severe (n=4) 
 Start End  Start End 
      
Age (years)  5.3 ± 1.7 6.4 ± 1.7  2.9 ± 0.9 3.9 ± 1.0 
Weight (lb) 496 ± 30 639 ± 27  484 ± 47 619 ± 81 
Backfat (cm) 6.3 ± 2.3 9.6 ± 0.2  7.9 ± 1.4 9.7 ± 1.1 
      
Insulin Sensitivity:      
Bergman Si (*start) 3.8 ± 0.2 3.5 ± 0.3  4.3 ± 0.1 3.7 ± 0.3 
Fasting insulin (µU/ml) 8.0 ± 2.3 14.5 ± 2.3  11.1 ± 5.1 17.9 ± 11.1
Fasting glucose (mg/dl) - sedated 110 ± 11 122 ± 8  101 ± 18 119 ± 21 
Fasting glucose (mg/dl)  - 
conscious 71 ± 6 79 ± 10  80 ± 11 75 ±2 
Fructosamine (mmol/L) († end) 1.4 ± 0.2 1.4 ± 0.1  1.5 ± 0.2 1.6 ± 0.2 
      
Lipid analysis:     
Total cholesterol (mg/dl) (*start) 64 ± 9 357 ± 73  97 ± 21 389 ± 91 
LDL cholesterol (mg/dl) († start) 36 ± 9 148 ± 7  56 ± 14 171 ± 32 
HDL cholesterol (*end) 33 ± 7 102 ± 12  38 ± 9 72 ± 12 
Triglycerides (mg/dl) 20 ± 9 25 ±17  25 ± 12 29 ± 14 
oxLDL (U/L) († start and end) 19.6 ± 2.5 28.7 ± 3.4  23.0 ± 1.6 36.1 ± 5.2 
      
Blood Pressure:      
Systole 157 ± 35 156 ± 21  133 ± 8 140 ± 11 
Diastole 98 ± 22 107 ± 17  86 ± 9 98 ± 9 
Mean arterial pressure 122 ± 29 126 ± 19  103 ± 10 112 ± 10 
Pulse 79 ± 15 92 ± 11  102 ± 17 97 ± 10 
      
Aldosterone (pg/ml) 207 ± 97 208 ± 98  210 ± 115 236 ± 53 
      
Inflammatory markers:      
TNFα (pg/ml) 11.3 ± 22.5 69.3 ± 59.3  3.0 ± 5.9 63.4 ± 52.5 
IL-6 (pg/ml) 13.4 ± 15.9 ND  ND 43.2 ± 86.4 
PAI-1 (ng/ml) 1.6 ± 2.5 0.7 ± 0.5  3.1 ± 3.4 1.3 ± 1.1 
CRP(µg/ml) 7.8 ± 4.6 4.5 ± 3.7  10.1 ± 8.9 18.8 ± 16.1 
*p<0.05 between groups, †trend toward significance (p=0.051-0.067)
 Purity of Endothelial Samples 
First pass and second pass coverslips with frozen aortic endothelium were 
used to establish endothelial purity.  First pass coverslips appeared fairly 
homogenous for ECs as seen by VWF staining (Figure 3.2).  While second pass 
coverslips still contained some ECs, smooth muscle cells (SMC) predominate as 
seen by staining for SMC actin (Figure 3.2).  Only first pass coverslips were used for 
RNA isolation. 
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 Figure 3.2.  VWF and SMC staining of aortic cells obtained by frozen coverslip 
technique.  To ensure a pure population of endothelial cells, coverslips were stained for 
VWF (red), smooth muscle cell actin (green), and DAPI (blue-nuclei).  The first pass is the 
first time a coverslip is frozen over a particular area and should recover only the endothelial 
cell monolayer.  First pass cell layers are shown from normal aorta (A) and atherosclerotic 
aorta (B). The second pass is the second time a coverslip is frozen over the same area and 
should pick up the underlying smooth muscle cells. Second pass cell layers are shown from 
normal aorta (C) and atherosclerotic aorta (D).  Secondary antibody control is also shown 
(E).  In our preparations, the first pass picked up only ECs as evidenced by VWF staining 
and not SMC staining.  Therefore, only first pass coverslips were used for EC RNA.  
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Gene Expression 
Aortic endothelial cells were collected from normal and atherosclerotic areas 
of abdominal aorta in pigs with severe atherosclerosis and pigs with moderate 
atherosclerosis.  The ratio of normalized expression intensities after hybridization of 
amplified RNAs to the Affymetrix Porcine Gene Chip were evaluated as below to 
determine which genes were significantly up or down regulated in the 
severe/moderate atherosclerotic endothelium vs. matched normal endothelium, and 
in the comparison of severe versus moderate disease.   
 
Severe vs. moderate disease 
Initial analysis looked for the genes which were up- or down-regulated in both 
normal and atherosclerotic endothelium of severe vs. moderate disease (1-severe 
disease, normal endothelium vs. moderate disease, normal endothelium and 2- severe 
disease, atherosclerotic endothelium vs. moderate disease, atherosclerotic 
endothelium).  Gene changes common to both normal and atherosclerotic endothelium 
are shown in Table 3.3.  There were five genes that were up-regulated in both groups 
(PTPRM, FAM5C, CLOCK, MYCPBP, LPHN2, HIPK2).  Three down-regulated genes 
were identified in both groups (TMSB4X, EIF2S3, JARID1C).  Genes unique to either 
normal or atherosclerotic endothelium of the severe group are shown in Table 3.4.  
They include SERPINI1 for the normal endothelium and MERP1 and RABGAP1L for 
the atherosclerotic endothelium. 
  
 Table 3.3. Comparison of Severe disease to Moderate disease – gene changes common to both normal and atherosclerotic 
endothelium (fold change is severe disease, normal endothelium-SN over moderate disease, normal endothelium-MN and severe 
disease, atherosclerotic endothelium-SA over moderate disease, atherosclerotic endothelium-MA) 
Gene 
designation  
 
Gene name 
  
Function 
 SN vs. MN  SA vs. MA 
 
Fold 
change 
p   
Fold 
change 
p 
     
TMSB4X  thymosin beta 4, X-linked  
cytoskeleton 
cell proliferation, migration, 
and differentiation 
 
-1310.53 1.76E-09  -1588.23 1.42E-09 
           
EIF2S3  Eukaryotic translation initiation factor 2 subunit 3   
translation 
VEGF signaling 
 -361.009 8.32E-11  -440.476 6.39E-11 
           
JARID1C  Jumonji/ARID domain-containing protein 1C   
transcription 
oxidoreductase activity 
 -44.2064 3.64E-06  -33.5628 6.43E-06 
           
           
HIPK2  Homeodomain-interacting protein kinase 2   
Apoptosis 
TGF-β signaling 
 16.5955 7.04E-07  18.6776 5.12E-07 
           
LPHN2  Latrophilin 2 precursor   Cell adhesion Signal  transduction 
 147.408 1.20E-08  91.0159 2.67E-08 
           
MYCPBP  c-myc promoter binding protein  Regulation of transcription  459.86 3.79E-12  484.71 3.54E-12 
           
CLOCK  Circadian locomoter output cycles kaput protein   transcription 
 674.391 2.57E-11  563.496 3.22E-11 
           
FAM5C  Family with sequence similarity 5, member C  
Migration, invasion 
hypertension 
 840.099 1.74E-10  667.556 2.29E-10 
           
PTPRM  Receptor-type protein-tyrosine phosphatase mu precursor   
Cell adhesion 
Negative regulation of 
angiogenesis, EC migration, 
and  EC proliferation 
hypertension 
 
826.804 5.48E-10  828.515 5.47E-10 
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Table 3.4. Comparison of Severe disease to Moderate disease - genes unique to normal or atherosclerotic endothelium of severe 
disease group (fold change is severe over moderate) 
Gene designation  Gene name 
 
Function 
 
Fold change p  
        
Normal 
endothelium     
 SN vs. MN  
SERPINI1  Serine proteinase  inhibitor 12  
regulation of cell adhesion 
cell death 
serine-type endopeptidase 
inhibitor activity 
 
3.2942 3.58E-06 
        
Atherosclerotic 
endothelium     
 SA vs.MA  
MERP1  Mammalian ependymin related protein-1 precursor  cell-matrix adhesion  8.76324 1.97E-06 
RABGAP1L  RAB GTPase activating protein 1-like  GTPase activator activity  3.24004 6.93E-08 
        
 
 Normal vs. atherosclerotic endothelium 
A second analysis evaluated genes that were up or down regulated in the 
atherosclerotic endothelium of each disease group vs. their respective normal 
endothelium (1-severe disease, atherosclerotic endothelium vs. severe disease, 
normal endothelium and 2- moderate disease, atherosclerotic endothelium vs. 
moderate disease, normal endothelium).  Gene changes common to both severe 
and moderate disease are shown in Table 3.5.  These common changes include 
down-regulation of two genes (KLHL13, SYNJ1) and up-regulation of four genes 
(FAP, COL4A1, COL4A2, CYP7B1).  Gene changes unique to severe disease, 
atherosclerotic endothelium are shown in Table 3.6.  Two genes (MERP1, 
RABGAP1L) are the same as seen by the previous analysis (Table 3.4) and fold 
changes were comparable to the previous analysis.  COL12A1 was additional up-
regulated.  For completeness, genes unique to moderate disease, atherosclerotic 
endothelium are shown in Table 3.7. 
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 Table 3.5. Comparison of atherosclerotic to normal endothelium – gene changes common to both severe and moderate 
disease groups (fold change is severe disease, atherosclerotic endothelium-SA over severe disease, normal endothelium-SN and 
moderate disease, atherosclerotic endothelium-MA over moderate disease, normal endothelium-MN) 
Gene 
designation  
 
Gene name 
  
Function 
 SA vs. SN  MA vs. MN 
 Fold change p  
Fold 
change p 
           
KLHL13  Kelch-like protein 13   protein binding  -4.37148 2.18E-05  -3.99779 3.44E-05 
           
SYNJ1  Synaptojanin 1   Inositol Phosphate Metabolism  -2.49799 2.03E-06  -2.55892 1.66E-06 
           
           
KIAA1715  Lunapark  blood coagulation  6.95726 1.88E-05  12.8776 2.39E-06 
           
CYP7B1  Cytochrome P450 7B1   
cholesterol metabolic process 
lipid metabolic process 
oxidation reduction 
 
31.7243 1.09E-06  69.8156 2.23E-07 
           
COL4A2 
(2hits)  Collagen, type IV, alpha 2   
extracellular matrix 
organization 
negative regulation of 
angiogenesis 
 
33.4807 
31.0193 
1.82E-05 
2.28E-05  
57.6233 
39.4786 
6.26E-06 
1.39E-05 
            
COL4A1  Collagen alpha 1(IV) chain precursor  
extracellular matrix structural 
constituent 
platelet-derived growth factor 
binding 
 
54.6855 1.75E-05  73.9564 1.02E-05 
           
FAP  Seprase   metalloendopeptidase activity  86.9546 8.65E-07  83.5107 9.28E-07 
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Table 3.6. Comparison of atherosclerotic to normal endothelium – genes unique to atherosclerotic endothelium of the severe 
disease group (fold change is severe disease, atherosclerotic endothelium-SA over severe disease, normal endothelium-SN) 
Gene 
designation  Gene name 
 Function  Fold change p  
      SA vs. SN  
RABGAP1L  RAB GTPase activating protein 1-like  GTPase activator activity 
 
2.72829 2.38E-07 
        
MERP1  Mammalian ependymin related protein-1 precursor   cell-matrix adhesion 
 
10.5267 1.06E-06 
        
COL12A1  Collagen alpha 1(XII) chain precursor  
extracellular matrix structural constituent 
cell adhesion 
 
54.8302 2.27E-05 
 
 
 Table 3.7. Comparison of atherosclerotic to normal endothelium – genes unique to atherosclerotic endothelium of the moderate 
disease group (fold change is moderate disease, atherosclerotic endothelium-MA over moderate disease, normal endothelium-MN) 
Gene 
designation  Gene name  Function 
 Fold change p 
      MA vs. MN  
PYGB  Glycogen phosphorylase  carbohydrate metabolism  -2.34974 2.72E-05 
        
GRB10  Growth factor receptor-bound protein 10   
cell-cell signaling, insulin-like growth factor 
receptor signaling pathway, negative regulation of 
glucose import, negative regulation of insulin 
receptor signaling pathway, signal transduction  
 
2.17855 1.61E-05 
        
PLXNB2  Plexin B2 precursor   signal transduction cell migration 
 2.7376 3.53E-05 
        
FGF18  Fibroblast growth factor-18 precursor   
fibroblast growth factor receptor binding, growth 
factor activity 
 3.89323 4.31E-05 
        
COL3A1 
(2 hits)  
Collagen alpha 1(III) chain 
precursor.   
extracellular matrix structural constituent, integrin 
binding, platelet-derived growth factor binding 
 7.30677 
24.9137 
1.24E-05 
3.54E-06 
        
TPM2 
(2hits)  Tropomyosin beta chain   actin binding, protein binding 
 8.66148 
8.7091 
2.71E-05 
7.06E-06 
        
PIK3R3  Phosphatidylinositol 3-kinase regulatory gamma subunit   insulin receptor signaling pathway 
 10.2481 5.60E-05 
        
ABI3BP  Target of Nesh-SH3 precursor   extracellular matrix organization, positive regulation of cell-substrate adhesion 
 10.7799 4.00E-05 
        
SLIT3  Slit homolog 3 protein precursor   calcium ion binding, protein binding, receptor binding, structural molecule activity  
 12.5587 4.68E-05 
        
ADORA1  Adenosine A1 receptor  
activation of MAPKK activity, cell-cell signaling, 
inflammatory response, positive regulation of 
blood pressure 
 
13.4092 4.81E-05 
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Table 3.7.  Continued 
Gene 
designation  Gene name  Function 
 Fold change p 
        
BCHE  Cholinesterase precursor   
carboxylesterase activity, choline binding, 
cholinesterase activity, enzyme binding, hydrolase 
activity 
 
24.9536 1.84E-05 
        
        
ACTA2  alpha 2 actin  
cell motility, structure and integrity 
Integrin Signaling  
Leukocyte extravasation signaling  
NRF2-mediated oxidative stress response  
VEGF Signaling  
 
25.9124 6.56E-06 
        
COL4A1  Collagen alpha 1(IV) chain precursor  
binding, extracellular matrix structural constituent, 
platelet-derived growth factor binding  
 63.2243 4.63E-05 
 Discussion  
Our goal was to identify molecular targets by comparing differential gene 
expression from normal and atherosclerotic aortic endothelial cells obtained from 
insulin resistant pigs with moderate and severe aortic atherosclerotic disease. These 
pigs were fed a high fat diet for one year and segregated into two groups with 
varying atherosclerotic severity.  The group with severe atherosclerosis had higher 
oxLDL and greater increases in fructosamine values consistent with increased 
oxidative stress than the group with moderate atherosclerosis.  
For many years, oxLDL has been postulated to alter endothelial barrier 
function[136] and may do so via changes in cytosolic calcium and subsequent 
reorganization of the cytoskeleton.[137]  Even mildly oxidized LDL was shown to 
cause rapid actin cytoskeleton organization.[138]  The cytoskeleton plays an 
essential role in endothelial repair as well.[139]  Endothelial integrity is maintained 
through tight complexes with neighboring cells.  Cadherins, calcium dependent 
adhesion molecules, play an important role in cell-cell interactions and are regulated 
by tyrosine phosphorylation.  Cadherins interact with catenins, which in turn link 
cadherins to the actin cytoskeleton.  Cadherin function is also regulated by Rho and 
Rac.  Rho regulates stress fiber formation and is controlled by three regulatory 
proteins: GDIs, GEFs, and GAPs.  GAPs in turn stimulate GTPase activity. 
 
In the present study many of the genes identified as differentially expressed in 
the severe disease group may be involved in cell adhesion/cytoskeletal signaling 
pathways.  The gene with highest increase was PTPRM which encodes receptor- 
type protein tyrosine phosphatase mu precursor.  The presence of PTPRM in 
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 vascular endothelium, especially in large arteries, has been established with 
localization at sites of cell-cell contact .[140]  It has been associated with cadherins 
in various tissues, in regulating cadherin function[141]  and is thought to play an 
important role in controlling the integrity of endothelial cell junctions[140] thus 
preserving the endothelial barrier.[142]  It would be expected that increased PTPRM 
would protect against increases in endothelial permeability and may seem counter 
intuitive that it is increased in the severe disease group. However, ex vivo studies of 
porcine endothelial cells exposed to shear stress for extended periods of time show 
that changes in both localization as well as protein levels of VE-cadherin and 
catenins are transient and return to a steady state.[143] PTPs may have transient 
changes due to the tight association of PTPs with these adhesion proteins.  It has 
also been show that the intracellular domains of PTPmu may be required to restore 
cell adhesion mediated by E-cadherin[144] and that PTPmu may indirectly influence 
other downstream signaling events, including negative regulation of 
angiogenesis.[145]  
A large decrease was seen in the expression of TMSB4X which encodes 
thymosin-beta 4. Thymosin B4 inhibits the polymerization of actin monomers and 
thus plays a role in actin polymerization. In addition to its role in actin polymerization, 
it is also involved in cell proliferation, migration, and differentiation.  It has been 
shown in murine bone marrow ECs (where it has significant inhibitory effects on cell 
proliferation)[146, 147], and cultured human umbilical ECs (where it increased the 
production of matrix metalloproteinases and induction of the PAI-1 gene)[148-150], 
as well as in a variety of tumor cells.[151-154] Perhaps the property most relevant to 
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 the current study is the ability of thymosin B4 to inhibit the inflammatory 
response[155, 156]  and the further suggestion that a decrease in TMSB4X gene 
expression and its subsequent protein may lead to increased inflammatory events in 
the endothelium.  
Other genes differentially expressed in the severe group included LPHN2 
(encodes latrophilin 2 precursor, a G-protein coupled receptor[157] which may 
facilitate calcium signaling in the cell[158]), HIPK2 (encodes homeodomain 
interacting protein kinase, a transcriptional cofactor which regulates apoptosis[159], 
cell growth and proliferation[160]), and FAM5C (encodes family with sequence 
similarity 5, member C which promotes proliferation, migration and invasion in 
neuronal and fibroblasts cells[161] as well as aortic smooth muscles cells[162]).  
Several other genes involved in transcription and translation were also noted: 
CLOCK, MYCPBP, JARID1C, EIF2S3 (Table 3.3). 
Gene changes common to the atherosclerotic endothelium of the severe 
disease group were identified using two different analysis groupings.  Fold changes 
were comparable between the two analyses (Tables 3.4 and 3.6).  MERP-1, 
RABGAP1L, and COL12A1 were up-regulated unique to atherosclerotic endothelium 
of the severe disease group.  COL12A1 encodes the alpha chain of type XII 
collagen.  It is a member of the fibril-associated collagens with interrupted triple 
helices family of extracellular matrix proteins and is thought to bridge the interactions 
of collagen I fibrils with the surrounding matrix[163] and may play a part in tissue 
remodeling[164].  MERP-1 encodes mammalian ependymin related protein-1 
precursor and has been shown to be expressed at high levels in human CD34+ 
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hematopoietic stem cells (where it may play a role in proliferation and differentiation) 
as well as in brain, heart, skeletal muscle and malignant tissues.[165]  It is thought to 
be a Type II transmembrane glycoprotein with possible calcium binding capabilities 
suggesting a possible role in calcium dependent cell adhesion.[166]  RABGAP1L 
encodes RAB GTPase activating protein1-like.  RAB GTPases are part of the Ras 
superfamily of monomeric G proteins and are involved in membrane traffic 
pathways[167, 168].  RABGAP1L was found to be down regulated in platelets of a 
patient with inherited platelet dysfunction and was linked to impaired integrin 
activation[169]. 
Interestingly, only one gene was found to be differentially expressed in normal 
endothelium of the severe disease group.  SERPINI1 encodes serine proteinase 
inhibitor 12.  It has been identified in neural cells (where it regulates axonal 
outgrowth[170]), glioblastoma[171], endocrine cells (where it may function in cell 
adhesion, communication and/or migration[172, 173]), and hepatocellular carcinoma 
(where its presence may serve as a diagnostic aid[174]).  While SERPINI1 has not 
been reported in endothelial cells its identification in normal endothelium from the 
severe disease group only may put it at the top of the list as a candidate for 
investigating potential areas of atherosclerosis development.  
To our knowledge, this is the first report linking a number of these genes to 
aortic atherosclerosis. A replicate study with a larger number of animals is underway 
to substantiate these data.  Genes identified through this and further studies can 
hopefully be used to develop novel methods for the noninvasive detection of 
endothelial dysfunction that occurs during atherogenesis. 
 Chapter 4 
Albuminuria and Renal Histopathology in Hyperlipidemic, 
Hyperinsulinemic Swine 
 
Abstract 
 
Human diabetic nephropathy is characterized by progressive renal 
insufficiency, albuminuria, and characteristic histopathology.  Both insulin resistance 
(IR) without overt diabetes as well as hyperglycemia in diabetes are risk factors for 
chronic renal disease in humans.  Objective:  To determine the extent of renal 
dysfunction and histopathology in hypercholesterolemic IR pigs and if these changes 
mirror the nephropathy seen in IR humans.  Methods:  18 adult IR pigs were fed a 
high fat diet (DH) and 6 adult familial hypercholesterolemic (FH) insulin sensitive (IS) 
pigs were fed a low fat diet for 12 months.  Urine was analyzed for 
albumin/creatinine ratio (UA/C) and kidneys for histopathology. Results:  All pigs had 
comparable hypercholesterolemia.  One IR pig died with renal failure after 3 months 
on study (serum creatinine 9.4 mg/dl).  No other pig had an increase in serum 
creatinine.  9/18 DH-IR pigs that completed 12 months of study had UA/C >30 and 
these 9 had higher blood pressure, aldosterone, and renal histopathology:  
glomerulosclerosis, tubulointerstitial fibrosis, and arteriolar hyalinosis (p < 0.04), as 
well as mesangial matrix expansion, decrease in podocyte density, and 
 
 
 glomerulobasement membrane thickening.  0/6 FH-IS pigs had a UA/C> 30 or renal 
histopathology.  Conclusion:  Renal histopathology in DH-IR pigs appears to mirror 
the human phenotype of an insulin resistant and/or diabetic nephropathy when 
moderate blood pressure elevation, increased aldosterone, and UA/C >30 are 
present.  These data also suggest that IR is necessary but insufficient for 
nephropathogenesis in pigs.   
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 Introduction 
Both insulin resistance (IR) without overt diabetes as well as hyperglycemia in 
diabetes are risk factors for chronic renal disease in humans.  IR is generally a 
precursor of type 2 diabetes mellitus (DM), in which there is improper use of insulin 
by muscle, fat, and liver cells.  Compensatory insulin secretion by the pancreas 
leads to increased insulin in the blood. When the pancreas can no longer 
compensate for the needed increase in insulin, glucose increases as well.  Patients 
with high normal glucose and increased insulin are in a “pre-diabetic” state.  
According to the US Department of Health and Human Services, there is an 
increased prevalence of pre-diabetes in the US.  Many of these patients go on to 
develop DM.  The incidence of insulin resistant, type 2 DM is increasing at epidemic 
rates globally.  In the United States alone, in 2007, there were 1.6 million new cases 
of diabetes diagnosed in people aged 20 years or older and a total of 7.8 percent of 
the population with diabetes.[1]  
Insulin resistance and hyperinsulinemia have been independently associated 
with chronic kidney disease in numerous analyses[19, 175, 176], showing significant 
correlations with albuminuria[176-179] and decreased renal function[180].  Insulin is 
thought to alter urinary sodium excretion by effects on the tubules, to promote 
mesangial cell proliferation, and increase the action of angiotensin II.[19]  Insulin 
resistance may be an independent predictor of the development of nephropathy in 
diabetics.  Progression to human diabetic nephropathy leads to a clinical syndrome 
characterized by progressive renal insufficiency in the setting of diabetes, 
albuminuria, and characteristic pathological changes[181-183] including mesangial 
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 matrix expansion and sclerosis, arteriolar hyalinosis, glomerulobasement membrane 
thickening, tubulointerstitial fibrosis, a general absence of immune complex deposits, 
and podocyte changes (including drop out and foot process effacement).   
Creation of an animal model of diabetic nephropathy is a major goal of the 
Animal Models of Diabetic Complications Consortium (AMDCC, www.amdcc.org) 
and considerable progress towards this goal has been made in mice.[182]  To date, 
few pig models of insulin resistance and diabetes have focused on nephropathy.[23, 
184]  Our goal was to characterize the extent to which functional and anatomic renal 
changes occur in diet-induced hypercholesterolemic, insulin resistant (DH-IR) pigs 
and, most importantly, how closely these changes resemble those found in humans 
with IR[175] and/or type 2 diabetes.  These data will be essential for the design of 
future mechanistic studies that will characterize the mechanisms that mediate the 
pathogenesis of nephropathy in insulin resistant states. 
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 MATERIALS AND METHODS 
Experimental Pigs, High Fat Diet, and Sampling Protocol during Year Long Study 
All pigs were treated according to the standards set in the Guide for Care and 
Use of Laboratory Animals (National Institutes of Health publication No. 85-23).  All 
procedures and protocols were in accordance with institutional guidelines and 
approved by the Institutional Animal Care and Use Committee.  All pigs were 
produced and maintained in the same environmental conditions at the Francis Owen 
Blood Research Laboratory at the University of North Carolina at Chapel Hill.   Male 
and female pigs were from Spotted Poland/China and Yorkshire crosses. The mean 
age at study entry was 3.3 ± 2.0 yr.  Pigs from the following three genotypes were 
used: normocholesterolemic (n=11), heterozygous familial hypercholesterolemic 
(n=8) and familial hypercholesterolemic (n=6).[50-52] Both normocholesterolemic 
and heterozygous familial hypercholesterolemic (FH) pigs do not express 
hypercholesterolemia unless they are fed a high fat diet.  These animals were fed a 
high fat diet that consisted of pig chow (5NP8 Wayne™ 15% Pig & Sow Pellets, 
Granville Milling, Granville NC) supplemented with 1% cholesterol, 20% beef tallow, 
and 0.75% cholate by weight.[53, 54] The NaCl content of the diets was measured 
(Eurofins Scientific Inc, Des Moines, IA) and 5NP8 provided 0.35% or 8 grams/day 
as recommended[55] and the high fat diet provided 0.55% or 12.5 grams/day, a 56% 
increase.  The total calories in this diet were distributed as: 43% fat, 12.5% protein, 
and 44.5% carbohydrate.   Familial hypercholesterolemic pigs exhibit spontaneously 
89 
 elevated levels of cholesterol and were fed normal pig chow (5NP8 Wayne™ 15% 
Pig & Sow Pellets, Granville Milling, Granville NC).   
The variables that were measured at baseline, 3, 6, and 12 months included:  
weight, backfat, blood pressure, insulin sensitivity, total and LDL and HDL 
cholesterol, triglycerides, serum creatinine, inflammatory makers, oxidized LDL, 
fructosamine, and aldosterone.  For detailed methods used to measure each of 
these variables, see Chapter 1 – Methods section. 
At study termination all pigs were euthanized with an overdose of 
pentobarbital (6 grains/ 10 lbs. IV) and urine and kidney samples for morphometry 
were collected.    
 
Kidney Morphometry 
Formalin fixed, paraffin embedded kidney sections were stained with PAS 
and evaluated for glomerulosclerosis, glomerular mesangial matrix expansion, 
arteriolar hyalinosis, and tubulointerstitial fibrosis.  On average, 50 glomeruli per pig 
were evaluated, only glomeruli with hylum or near equatorial plane were included in 
the analysis.  Glomerulosclerosis is described as a percent (sclerotic glomeruli per 
total glomeruli).  Morphometric analysis used Image J to measure diameter, 
circumference, area, and nuclei count of non-sclerotic glomeruli.  Mesangial matrix 
area was assessed by using Image J to measure PAS stained area of mesangium. 
Mesangial matrix area is expressed as average area per glomerular section.  Nuclei 
were counted in each glomerular section and expressed as number of nuclei per 
glomerular section.  Kidneys were also processed for electron microscopy by 
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 standard methods.  Calibrated, digital micrographs were taken of nine random areas 
of glomerulobasement membrane (GBM) from each pig.  Image J was used to 
measure GBM thickness.   
Podocytes were visualized in frozen kidney sections placed onto Probe-On 
Plus charged microscopic slides, dried, and fixed in acetone and paraformaldehyde.  
Endogenous peroxidases were quenched by exposure of the tissue sections to a 
hydrogen peroxide/methanol solution before antigen retrieval was performed.    Non-
specific binding was blocked by exposure of the sections to avidin D and biotin 
solutions and 2% horse serum (Vector Laboratories).  The kidney sections were 
incubated with anti-WT-1(Wilm’s tumor antigen 1, 1:200 dilution, C-19, Santa Cruz 
Biotechnology, CA) overnight at 4°C. (WT-1 is a marker for mature, differentiated 
podocytes.[185])  This was followed by incubation with a universal secondary 
antibody and Vectastain R.T.U. Elite ABC reagent supplied in the Vectastain 
Universal Elite ABC kit (Vector Laboratories).  The stain was visualized using 
NovaRed (Vector Laboratories) and counterstained with PAS for enhanced contrast.  
Omitting the primary antibody created negative controls.  WT-1 positive nuclei were 
counted in each glomerular section and expressed as a percent of the total number 
of nuclei. 
 
Urine Albumin and Creatinine 
Urinary albumin was measured by ELISA (Bethyl Labs, Montgomery, TX, 
sensitivity 7.8 ng/ml, Pig Albumin) and urine creatinine was measured by automated 
methods (Antech).  The reference interval for normal human urine albumin/creatinine 
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 ratio (UA/C) is 0-30 µg albumin/mg creatinine, microalbuminuria is 30-300 and clinical 
albuminuria is >300.  Since reference ranges have not been established for insulin 
resistant pigs, we have tentatively used human ranges as guidelines for evaluating 
urinary albuminuria.  
 
Statistical Analysis  
Descriptive statistics for weight, backfat, blood pressure, triglycerides, total 
and LDL and HDL cholesterol, oxLDL, fructosamine, inflammatory markers, insulin, 
glucose, Bergman Si values, and kidney morphometry measurements are reported 
for all groups as means ± SD.  The Wilcoxon rank sum test was used to assess 
within group change and for pair wise comparisons of conditions between groups.  A 
p value of < 0.05 was considered significant. 
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 Results  
Twenty five pigs were entered into the year-long study. Nineteen 
normocholesterolemic hyperinsulinemic pigs were fed a high fat diet to induce 
hypercholesterolemia (DH) and developed worsening insulin resistance (IR) when 
eating this diet.  Six familial hypercholesterolemic (FH) insulin sensitive (IS) pigs 
were used as controls. All pigs had comparable hypercholesterolemia.  The detailed 
results of the renal evaluation are presented first followed by the metabolic 
parameters that were monitored during the yearlong study to determine which were 
associated with the development of nephropathy.   
One DH-IR pig died with renal failure after 3 months on diet (serum creatinine 
9.4 mg/dl) and was excluded from further study.  Urine was not available from this 
pig, however several of the histopathological findings consistent with insulin 
resistant/diabetic nephropathy were present, most notably, mesangial sclerosis, 
GBM thickening, tubulointerstitial fibrosis, podocyte foot process effacement, and 
protein resorption droplets in renal tubules.   
 
Albuminuria 
None of the six control FH-IS pigs had an elevated UA/C. Urine was not 
available from one of the DH-IR pigs and this pig was excluded from further analysis.  
Of the remaining 17 DH-IR pigs, eight (47%) had a UA/C <30 and nine (53%) had 
UA/C >30 (Figure 4.1).   
93 
  
 
Figure 4.1.  Albuminuria in IS and IR pigs.  None of the six control FH-IS pigs 
exhibited albuminuria.  Eight (47%) of the DH-IR pigs had a UA/C <30 and nine (53%) 
had UA/C >30.  The reference interval for normal human urine albumin/creatinine 
ratio (UA/C) is 0-30 µg albumin/mg creatinine, microalbuminuria is 30-300 and clinical 
albuminuria is >300.  Since reference ranges have not been established for insulin 
resistant pigs, we have tentatively used human ranges as guidelines for evaluating 
urinary albuminuria.  
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 Renal Histopathology 
The FH-IS pigs exhibited no detectible renal histopathology (Table 4.1).  Four 
of the eight DH-IR pigs with UA/C <30 had glomerulosclerosis, six had mesangial 
matrix expansion, and five had podocyte changes (Table 4.1).  The 
glomerulosclerosis was perihylar and focal segmental.  Tubulointerstitial fibrosis, 
arteriolar hyalinosis and GBM thickening were not detected in any of the DH-IR pigs 
with UA/C <30.   Seven of the nine DH-IR pigs with UA/C >30 had glomerulosclerosis, 
six had mesangial matrix expansion, six had tubulointerstitial fibrosis, four had 
arteriolar hyalinosis, two showed glomerulobasement membrane thickening, and 
seven had podocyte changes (Table 4.1, Figure 4.2). The glomerulosclerosis was 
predominantly perihylar and focal segmental, with three of the pigs also exhibiting 
global sclerosis. None of the pigs exhibited immune complex deposition (Table 4.1).    
95 
 96 
Table 4.1. Pig Demographic and Metabolic Characterization at End of 12 
Months of Study 
 FH-IS DH-IR 
Age (years) 2.9 ± 0.4 3.8 ± 1.0 5.3 ± 2.0 
Weight (lb) 484 ± 46 604 ± 86 661 ± 60 
Weight (% increase from baseline) 9.7 ± 5.1 23.7 ± 8.0 26.2 ± 6.2
Bergman Si 4.6 ± 0.4 3.4 ± 0.3 3.5 ± 0.4 
Fasting insulin (µU/ml) 7.6 ± 2.9 15.3 ± 4.0 19.7 ± 9.2
Fasting glucose (mg/dl) - sedated 76 ± 6 125 ± 28 116 ± 22 
Fasting glucose (mg/dl)  - conscious 71 ± 2 72 ± 4 76 ± 7 
Fructosamine (mmol/L) 1.9 ± 0.2 1.5 ± 0.2 1.5 ± 0.2 
Blood pressure (mmHG) 137/85 130/84 154/108* 
Mean arterial pressure 105 ± 20 100 ± 16 125 ± 17*
Aldosterone (pg/ml) 47 ± 16 175 ± 75 194 ± 94 
Total cholesterol (mg/dl) 383 ± 43 333 ± 74 385 ± 63 
Serum creatinine (mg/dl) 2.3 ± 0.4 1.9 ± 0.3 1.5 ± 0.3 
Urine albumin/creatinine ratio:   
 UA/C >30 0/6 0/8 9/9* 
Average UA/C 9.7 ± 10.9 5.8 ± 6.1 181 ± 174*
Renal Histopathology:    
Glomerulosclerosis 0/6 4/8 7/9 
% glomeruli with sclerosis 0 4 ± 7 26 ± 16* 
Mesangial matrix (MM) expansion 0/6 6/8 6/9 
MM area (x103 µm2) 2.3 ± 0.6 3.8 ± 1.5 5.0 ± 1.9 
Tubulointerstitial fibrosis 0/6 0/8 6/9* 
Arteriolar hyalinosis 0/6 0/8 4/9* 
GBM thickening 0/6 0/8 2/9 
Thickness (nm) 161 ± 14 229 ± 41 210 ± 32 
Podocyte density  
(% of total cells in glomeruli) 14.5 ± 3.8 7.9 ± 2.1 7.3 ± 1.8 
Immune complex deposition 0/6 0/8 0/9 
Glomerular tuft area (x104 µm2) 2.2 ± 0.2 3.0 ± 0.3 3.6 ± 0.5*
Nuclei per glomerular section 179 ± 18 225 ± 18 248 ± 26*
*p<0.046 for DH-IR pigs with UA/C >30 vs. DH-IR pigs with UA/C>30
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 Figure 4.2.  Renal Histopathology in Hyperlipidemic, Hyperinsulinemic Pigs 
with UA/C >30.  Characteristic changes of renal pathology seen in humans with 
insulin resistance were also noted in the DH-IR pigs. They include both segmental 
(A) and global (B) sclerosis, arrows in B show residual fuchsinophilic (red) 
hyalinosis. Tubulointerstitial fibrosis (C and D) is seen by the pink area below the 
black line in C (red arrows, PAS staining) or the blue staining below the black line in 
D (small black arrow, Masson’s trichrome stain), indicating collagen deposition.  A 
sclerotic glomerulus is also noted by large black arrow (D); tubular atrophy (white 
arrows) and chronic inflammation (blue arrows) are also present in C.  Arteriolar 
hyalinosis (E) was also present as indicated by the black arrow.  
Glomerulobasement membrane thickening (F) is noted by the black arrows.  
Decrease in podocyte density is seen in G (podocyte detection by 
immunohistochemical staining with antibody to WT-1, C-19, Santa Cruz 
Biotechnology, Nova Red detection, arrows). Podocyte staining from FH-IS control 
pig for comparative purposes is seen in H. 
Magnification bars A, B, C, E, G, & H = 50 µm; D = 100 µm; F = 25 µm. 
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 Glomerular analysis – While the control FH pigs had no glomerulosclerosis, the 
DH-IR pigs with UA/C <30 averaged 3.9 ± 6.8 percent glomeruli with sclerosis.  Both 
were significantly lower than DH-IR pigs with UA/C >30 which averaged 25.9 ± 16.1 
percent glomeruli with sclerosis (Table 4.1, p<0.016).  Glomeruli from DH-IR pigs with 
UA/C >30 also had significantly larger tuft surface area than glomeruli from either DH-IR 
pigs with UA/C <30 or control FH-IS pigs (Table 4.1, p<0.008).  Both DH-IR groups 
showed an increase in mesangial matrix area.  The DH-IR pigs with UA/C >30 had a 
mesangial matrix area (MMA) of 5.0 ± 1.9 x 103µm2, and the DH-IR pigs with UA/C <30 
had an MMA of 3.8 ± 1.5 x 103µm2. These were significantly larger than in the control 
FH-IS pigs (2.3 ± 0.6 x 103µm2, p<0.043, Table 4.1).   
Glomerular cellularity was increased in both the DH-IR groups.  The DH-IR 
pigs with UA/C >30 had an average of 248 ± 26 nuclei per glomerular section which 
was significantly higher than either the DH-IR pigs with UA/C <30 (225 ± 18) or the 
control FH-IS pigs (179 ± 19, Table 4.1, p<0.046). 
There was a significant decrease in podocyte density between the DH-IR pigs 
and the control FH-IS control pigs (Figure 4.2, G & H).  In the FH-IS pigs 14.5 ± 
3.8% of the total cells were podocytes, compared to 7.9 ± 2.1% for the DH-IR pigs 
with UA/C <30 and 7.3 ± 1.8% for the DH-IR pigs with UA/C >30 (Table 4.1, p<0.005). 
While GBM thickening was noted by light microscopy on two of the DH-IR 
pigs with UA/C >30,  GBM thickness measurements taken from digital electron 
micrographs of nine random areas of GBM for each pig showed no significant 
difference in thickness between the two DH-IR groups. Both groups of DH-IR pigs 
had significantly thicker GBM measurements than the FH-IS pigs (Table 4.1, 
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 p<0.03). 
 
Creatinine 
Serum creatinine was not elevated in the study animals at any time point (Table 4.1). 
 
Fasting Insulin, Glucose, and Insulin Sensitivity by Bergman FSIVGTT and 
Fructosamine 
Fasting glucose values in conscious pigs at months 1, 2, 4, 5, 7, 8, 9, 10, and 
11 are shown in Table 4.2, and their counterparts for sedated pigs during the 
Bergman FSIVGTT at baseline, 3, 6, and 12 months are in Table 4.3.  The glucose 
values are higher when the pigs were sedated, possibly due to the stress of the 
procedure or the sedatives used.[84, 85]   
Fasting insulin values measured during the Bergman FSIVGTT were not 
significantly different between the three groups at baseline.  The DH-IR pigs with 
UA/C >30 had insulin levels significantly higher than the FH-IS pigs at 3, 6, and 12 
months (p<0.005).   The DH-IR pigs with UA/C <30 had insulin values significantly 
higher that the FH-IS pigs at 12 months (p<0.001).  The only difference in insulin 
values between the two DH-IR groups was at 3 months and was significantly higher 
in the DH-IR pigs with UA/C >30 (p<0.006).  The DH-IR pigs with UA/C >30 also had 
fasting insulin values significantly higher at 12 months compared to baseline (p ≤ 
0.004), whereas the DH-IR pigs with UA/C <30 and the FH-IS pigs showed little or no 
evidence of change  in insulin values over the 12 months on diet (Table 4.3).  
Fasting glucose values during the Bergman FSIVGTT showed little or no 
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 evidence of change over the 12 months on diet for any of the three groups.  There 
was no significant difference in glucose between the two DH-IR groups at any time 
point but both were significantly higher than the FH-IS pigs at all time points (p<0.05, 
Table 4.3).  
The mean Si values decreased significantly in the DH-IR pigs with UA/C >30 at 
3, 6 and 12 months and in the DH-IR pigs with UA/C <30 at 12 months consistent with 
increased insulin resistance (p <0.003 compared to baseline). There was no change 
in Si values for the control FH-IS pigs during the 12 months of study.  Si values for 
both DH-IR groups were significantly lower than FH-IS pigs at all time points 
(p<0.014, Table 4.3). 
Fasting fructosamine values are shown in Table 4.3.  Values for FH and DH-
IR pigs with UA/C <30 remained relatively unchanged over the 12 months of study.  
DH-IR pigs with UA/C >30 had significant increases over baseline at 3 and 6 months 
(p<0.02).  Values for FH pigs were significantly higher than both groups of DH pigs 
at all time points (p<0.02). 
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 Table 4.2.  Fasting Glucose in Conscious IS and IR Pigs on the Year Long 
Study 
      
 
FH-IS 
Ua/c<30 
(n = 6) 
 
DH-IR 
Ua/c<30 
(n = 8) 
 
DH-IR 
Ua/c>30 
(n = 9*) 
Fasting Glucose (mg/dl)      
Month:    1 76 ± 7  74 ± 8  73 ± 6 
2 66 ± 10  74 ± 6  74 ± 5 
4 71 ± 3  74 ± 7  76 ± 7 
5 71 ± 8  75 ± 13  72 ± 7 
7 72 ± 5  77 ± 8  72 ± 5 
8 71 ± 3  75 ± 9  73 ± 9 
9 71 ± 4  80 ± 15  72 ± 5 
10 71 ± 3  73 ± 12  75 ± 3 
11 71 ± 2  72 ± 4  76 ± 7 
      
*One pig was euthanized due to inappetance at 6 months, thus n = 8 for months 
7 to 11. 
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 Table 4.3.  Fasting Insulin and Glucose, Bergman Si, and Fructosamine Values 
       
  
FH-IS 
Ua/c<30 
(n = 6) 
 
DH-IR 
Ua/c<30 
(n = 8) 
 
DH-IR 
Ua/c>30 
(n = 9*) 
Fasting Insulin (µU/ml)       
Baseline  9.3 ± 2.4  11.0 ± 4.2  15.5 ± 12.7 
3 month  7.8 ± 1.4  11.6 ± 4.0  18.9 ± 4.4 
6 month  7.5 ± 1.2  14.4 ± 9.3  19.6 ± 14.5 
12 month  7.6 ± 2.9  15.3 ± 4.0  19.7 ± 9.2† 
       
Fasting Glucose (mg/dl)       
Baseline  88.0 ± 13.0  108.4 ± 19.6  114.6 ± 27.7 
3 month  75.4 ± 4.5  107.2 ± 22.4  106.5 ± 21.1 
6 month  77.6 ± 11.9  100.6 ± 19.7  117.0 ± 39.2 
12 month  75.6 ± 6.3  125.2 ± 27.7  116.2 ± 21.5 
       
Bergman Si       
Baseline  4.8 ± 0.6  4.0 ± 0.2  3.9 ± 0.5 
3 month  4.6 ± 0.5  3.9 ± 0.4  3.6 ± 0.4† 
6 month  4.5 ± 0.6  3.8 ± 0.4  3.5 ± 0.5† 
12 month  4.6 ± 0.4  3.4 ± 0.3†  3.5 ± 0.4† 
       
Fasting Fructosamine 
(mmol/L)       
Baseline  2.0 ± 0.3  1.5 ± 0.2  1.4 ± 0.1 
3 month  2.0 ± 0.1  1.7 ± 0.2  1.7 ± 0.2† 
6 month  2.1 ± 0.2  1.6 ± 0.2  1.6 ± 0.2† 
12 month  1.9 ± 0.2  1.5 ± 0.2  1.5 ± 0.2 
       
*One pig was euthanized due to inappetance at 6 months, thus n = 8 for month 12. 
†p<0.05, Wilcoxon signed rank statistic for change from baseline within group.
103 
 Weight and Backfat  
The baseline, 3, 6, and 12 month weight and backfat values are shown in 
Table 4.4.   Weight increased significantly over time compared to baseline in both 
the DH-IR pigs with UA/C >30 and the FH-IS pigs at 3, 6 and 12 months and in the 
DH-IR pigs with UA/C <30 at 6 and 12 months (p<0.04). The weights for DH-IR pigs 
with UA/C >30 were significantly increased compared to DH-IR pigs with UA/C <30 at 3 
months (p=0.010) and were also significantly increased at all time points compared 
to FH-IS pigs (p<0.016). The weights for DH-IR pigs with UA/C <30 were significantly 
increased over the FH-IS pigs at 12 months only (p=0.004).   
Backfat increased significantly in DH-IR pigs with UA/C >30 at all time points (p 
< 0.016).  There was no significant change in backfat for DH-IR pigs with UA/C <30 at 
any time point.  Backfat values were significantly different between the two DH-IR 
groups at 12 months (p=0.003).  Backfat values were not available for the FH-IS 
pigs. 
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 Table 4.4. Weight and Backfat in IS and IR Pigs in Year Long Study 
       
  
FH-IS 
Ua/c<30 
(n = 6) 
 
DH-IR 
Ua/c<30 
(n = 8) 
 
DH-IR 
Ua/c>30 
(n = 9*) 
Weight (lb)       
Baseline  421 ± 51  457 ± 41  512 ± 59 
3 month  457 ± 50†  479 ± 72  578 ± 47† 
6 month  449 ± 38†  525 ± 86†  606 ± 35† 
12 month  484 ± 46†  604 ± 86†  661 ± 60† 
       
Backfat (cm)       
Baseline  NA  6.2 ± 1.8  7.4 ± 2.0 
3 month  NA  7.4 ± 1.0  8.1 ±1.5† 
6 month  NA  7.8 ± 0.8  8.8 ± 1.4† 
12 month  NA  8.5 ± 1.1  9.9 ± 0.6† 
       
NA = not available.   
Data are listed for pigs for which there was a complete 12 month data set except for 
*one pig that was euthanized at 6 months due to inappetance, thus n = 8 for month 
12. 
†p<0.05, Wilcoxon signed rank statistic for change from baseline within group. 
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 Blood Pressure 
Blood pressure data are listed in Table 4.5.  Data are listed for pigs for which 
there was a complete 12 month data set except for one pig that was euthanized at 6 
months due to inappetance. Blood pressure values were only available for one FH-
IS pig at baseline and two FH-IS pigs at all other time points. 
Blood pressure in DH-IR pigs with UA/C >30 did not change significantly over 
the 12 months of study and was in a range that would be considered mildly 
hypertensive in humans.  Blood pressure in DH-IR pigs with UA/C >30 was 
significantly higher than DH-IR pigs with UA/C <30 at baseline, 3, and 12 months 
(p<0.045) and significantly higher than FH-IS pigs at 3 months (p=0.036).  
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 Table 4.5. Arterial Blood Pressure (mm Hg) in IR Pigs on the Year Long Study 
       
  
FH-IS 
Ua/c<30 
(n = 1,2) 
 
DH-IR 
Ua/c<30 
(n = 5) 
 
DH-IR 
Ua/c>30 
(n = 9*) 
Systolic       
Baseline  127  123 ± 7  144 ± 24 
3 month  126 ± 4  130 ± 8  147 ± 17 
6 month  121 ± 8  154 ± 24  146 ± 27 
12 month  137 ± 31  130 ± 16  154 ± 17 
Diastolic       
Baseline  86  73 ± 4  95 ± 13 
3 month  83 ± 1  80 ± 9  99 ± 16 
6 month  80 ± 6  101 ± 15  104 ± 31 
12 month  85 ± 25  84 ± 16  108 ± 14 
MAP       
Baseline  106  93 ± 7  114 ± 19 
3 month  101 ± 2  102 ± 6  121 ± 17 
6 month  94 ± 1  123 ± 22  120 ± 31 
12 month  105 ± 20  100 ± 16  125 ± 17 
Pulse       
Baseline  61  91 ± 11  99 ± 23 
3 month  94 ± 11  89 ± 11  105 ± 19 
6 month  86 ± 10  86 ± 17  109 ± 23 
12 month  81 ± 13  99 ± 18  96 ± 13 
       
Data are listed for pigs for which there was a complete 12 month data set except for 
*one pig that was euthanized at 6 months due to inappetance, thus n = 8 for month 
12. 
†p<0.05, Wilcoxon signed rank statistic for change from baseline within group. 
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 Aldosterone  
Aldosterone values are listed in Table 4.6.  DH-IR pigs with UA/C >30 had 
aldosterone values significantly higher than the FH-IS pigs at all time points 
(p<0.018).  DH-IR pigs with UA/C <30 had aldosterone values significantly higher 
than the FH-IS pigs at 3, 6, and 12 months (p<0.013).  While the mean aldosterone 
levels were higher in the DH-IR pigs with UA/C >30, they were not statistically 
different from the DH-IR pigs with UA/C <30. 
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 Table 4.6. Fasting Aldosterone Values in IS and IR Pigs 
       
  
FH-IS 
Ua/c<30 
(n = 6) 
 
DH-IR 
Ua/c<30 
(n = 8) 
 
DH-IR 
Ua/c>30 
(n = 9*) 
Aldosterone (pg/ml)       
Baseline  58 ± 24  127 ± 111  202 ± 108 
3 month  40 ± 12  125 ± 80  185 ± 100 
6 month  42 ± 32  126 ± 70  203 ± 85 
12 month  47 ± 16  175 ± 75  194 ± 94 
       
*One pig in this group was euthanized due to inappetance at 6 months, thus n = 8 
for month 12. 
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 Total, LDL, and HDL Cholesterol, oxLDL and Triglyceride Levels  
Lipoprotein values are listed in Table 4.7.  FH-IS pigs had no significant 
changes in total, LDL, and HDL cholesterol, oxLDL, or triglycerides at any time point.  
Both groups of DH-IR pigs had significant increases above baseline in total, LDL, 
and HDL cholesterol, and oxLDL at all time points (p<0.004).  The only significant 
difference seen between the DH-IR groups was in HDL cholesterol at baseline, DH-
IR pigs with UA/C >30 had a significantly higher value than DH-IR pigs with UA/C <30 
(p=0.016). 
FH-IS pigs had significantly higher total cholesterol at baseline than either 
group of DH-IR pigs (p<0.001). This due a LDL receptor mutation (i.e., not diet 
induced).  Total cholesterol levels were comparable between the three groups 
throughout the remainder of the study.  FH-IS pigs had significantly higher 
triglycerides at baseline than both DH-IR groups and significantly higher triglycerides 
at 3 months than the DH-IR pigs with UA/C <30 (p<0.008).  LDL cholesterol values 
were significantly higher at all time points for FH-IS pigs than either DH-IR group 
(p<0.013). FH-IS pigs had HDL cholesterol values significantly lower than DH-IR 
pigs with UA/C >30 at all time points and significantly lower than DH-IR pigs with UA/C 
<30 at 3, 6 and 12 months (p<0.001). FH-IS pigs also had oxLDL levels significantly 
higher than DH-IR pigs with UA/C <30 at baseline, 3 and 12 months and significantly 
higher than DH-IR pigs with UA/C >30 at baseline and 6 months (p<0.005). 
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 Table 4.7. Fasting Total, LDL, and HDL Cholesterol, oxLDL, and Triglyceride 
Levels  
       
  FH-IS  Ua/c<30  
(n = 6)  
 
DH-IR  
Ua/c<30  
(n = 8) 
 
DH-IR  
Ua/c>30  
(n = 9*) 
Total cholesterol 
 (mg/dl)       
Baseline  391 ± 104  69 ± 16  86 ± 18 
3 month  394 ± 54  434 ± 204†  435 ± 95† 
6 month  410 ± 73  402 ± 185†  317 ± 118† 
12 month  383 ± 43  333 ± 74†  385 ± 63† 
       
LDL cholesterol  
(mg/dl)       
Baseline  291 ± 76  36 ± 14  49 ± 11 
3 month  305 ± 43  198 ± 80†  201 ± 40† 
6 month  302 ± 48  174 ± 58†  151 ± 59† 
12 month  291 ± 27  134 ± 15†  172 ± 22† 
       
HDL cholesterol  
(mg/dl)       
Baseline  20 ± 4  26 ± 7  36 ± 6 
3 month  22 ± 4  95 ± 38†  91 ± 24† 
6 month  22 ± 4  85 ± 26†  82 ± 26† 
12 month  22 ± 3  77 ± 19†  84 ± 18† 
       
oxLDL (U/L)       
Baseline  42 ± 3  20 ± 2  22 ± 2 
3 month  40 ± 5  30 ± 6†  34 ± 6† 
6 month  40 ± 4  33 ± 8†  30 ± 6† 
12 month  40 ± 4  30 ± 6†  36 ± 5† 
       
Triglycerides (mg/dl)       
Baseline  56 ± 9  22 ± 6  24 ± 9 
3 month  35 ± 5  22 ± 8  31 ± 16 
6 month  46 ± 32  24 ± 14  26 ± 20 
12 month  32 ± 20  24 ± 13  25 ± 12 
       
*One pig in this group was euthanized due to inappetance at 6 months, thus n = 8 
for month 12. 
†p<0.05, Wilcoxon signed rank statistic for change from baseline within group. 
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 Inflammatory Markers  
Values for inflammatory markers are shown in Table 4.8.  DH-IR pigs with 
UA/C <30 had significant increases in TNFα and PAI-1 at 3 months compared to 
baseline (p<0.05).   DH-IR pigs with UA/C >30 had a significant increase in PAI-1 at 3 
months compared to baseline (p<0.02).   FH-IS showed no significant differences in 
inflammatory markers over the study period. 
There were no significant differences in any marker, at any time point 
between the two DH-IR groups.  TNFα values for DH-IR pigs with UA/C <30 were 
significantly increased at all time points compared to FH-IS pigs (p<0.033) and CRP 
values for DH-IR pigs with UA/C <30 were significantly lower than FH-IS pigs at 
baseline (p=0.008).  Significant differences between DH-IR pigs with UA/C >30 and 
FH-IS pigs included increased TNFα at 12 months and increased PAI-1 at 3 months 
(p<0.05). 
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 Table 4.8. Inflammatory Markers 
       
  
FH-IS 
Ua/c<30 
(n = 6) 
 
DH-IR 
Ua/c<30 
(n = 8) 
 
DH-IR 
Ua/c>30 
(n = 9*) 
TNF-alpha (pg/ml)       
Baseline  4.8 ±6.9  42.3 ± 40.0  17.5  ± 18.7 
3 month  9.4  ± 13.1  111.1 ± 91.6†  53.3 ± 72.0 
6 month  5.5  ± 8.5  61.9 ± 39.2  31.3 ± 35.2 
12 month  2.0  ± 0.0  101.8 ± 124.1  51.1 ± 58.2 
IL-6 (pg/ml)       
Baseline  12.0 ± 8.8  11.1 ± 11.9  7.9 ± 8.7 
3 month  8.9 ± 5.4  38.6 ± 43.7  10.6 ± 12.0 
6 month  9.7 ± 10.6  25.6 ± 58.4  5.0 ± 0.0 
12 month  5.0 ± 0.0  24.3 ± 27.6  26.0 ± 59.3 
PAI-1 (ng/ml)       
Baseline  1.7 ± 3.9  1.5 ± 1.2  4.4 ± 5.2 
3 month  3.1 ± 5.0  6.2 ± 4.8  10.6 ± 6.9† 
6 month  2.3 ± 1.7  3.1 ± 2.3  4.9 ± 4.9 
12 month  2.2 ± 2.1  3.0 ± 5.3  1.4 ± 1.3 
CRP (µg/ml)       
Baseline  37.7 ± 42.0  6.7 ± 11.5  8.8 ± 6.2 
3 month  10.6 ± 5.3  8.9 ± 5.2  16.3 ± 20.5 
6 month  40.0 ± 38.3  11.4 ± 9.6  8.8 ± 7.6 
12 month  26.1 ± 25.9  9.2 ± 9.7  13.4 ± 12.4 
*One pig was euthanized due to inappetance at 6 months, thus n = 8 for month 12. 
†p<0.05, Wilcoxon signed rank statistic for change from baseline within group. 
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 Discussion  
This study demonstrates renal histopathology consistent with human insulin 
resistant/pre-diabetic nephropathy in a subset of insulin resistant, 
hypercholesterolemic pigs fed a high fat diet with increased sodium content.  The 
two groups of DH-IR pigs were similar in degree of hyperinsulinemia, decrease in 
insulin sensitivity, weight gain, backfat, lipid profiles, and inflammatory markers.   
However, one group exhibits albuminuria, moderate elevation in blood pressure, and 
persistent elevations in aldosterone levels.  We must mention that none of these 
pigs became hyperglycemic (glucose > 126 mg/dl). While insulin resistance without 
overt hyperglycemia has been shown to be a risk factor for chronic renal disease, 
this study suggests that IR is necessary but insufficient for nephropathogenesis in 
our pigs. The scope of this paper is not meant to be mechanistic in nature, but to 
characterize the extent to which functional and anatomic changes occur in our 
insulin resistant (IR) pigs and, most importantly, how closely these changes 
resemble those found in humans with insulin resistance.   
 
Albuminuria 
Glomeruli act as a size and charge barrier to keep albumin and other proteins 
present in the blood from entering the urine.  When glomeruli are damaged, albumin 
is able to pass through and is then excreted in the urine.  The DH-IR pigs were 
segregated based on the presence or absence of albuminuria.  The presence of 
even small amounts of albumin in the urine, “microalbuminuria” (UA/C of 3-300), is 
often undetectable by urine dipstick, can occur long before the onset of overt 
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 nephropathy, and is an important finding as it indicates that there is already 
significant deterioration or impairment in renal function.  Albuminuria may be a 
transient finding; therefore the sustained presence of albuminuria (repeat sampling) 
is a more reliable indicator of glomerular damage.  In the current study, urine was 
only evaluated for albuminuria at the end of the 12 months of study.  In conjunction 
with the other findings of glomerular and tubular injury, we conclude that this is likely 
not a transient finding but a true indicator of renal disease in these animals.  
Additionally insulin resistance and hyperinsulinemia have been significantly 
associated with the presence of albuminuria in numerous studies.[19, 175, 176]  
 
Mesangial Expansion, Podocyte changes, and Glomerular hypertrophy 
Mesangial expansion can be caused by an increase in mesangial matrix 
and/or an increase in mesangial cells[186]. Studies have shown rat mesangial cells 
grown in vitro in the presence of supplemental insulin had alterations in their 
phenotype and the expression of collagens leading to increased cell proliferation and 
accumulation of extracellular matrix.[187, 188]  When compared to the insulin 
sensitive pigs, both groups of DH-IR pigs had increases in mesangial matrix as well 
as increased cellularity (Table 4.1).   
Mesangial matrix expansion may also result in part from reduced degradation 
because of a decrease in matrix metalloproteinases (MMP).  Plasminogen activator 
inhibitor 1 (PAI-1) has been shown in animal models to inhibit MMPs.[189]  While 
sustained increases of PAI-1 were not seen over the course of the study, both 
groups of DH-IR did have significant increases in PAI-1 at 3 months. 
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 Both groups of DH-IR pigs had a decreased number of podocytes compared 
to the FH-IS control pigs. Immortalized human podocytes have been shown to be 
insulin responsive[190] and podocyte number and density in patients with obesity 
related glomerulopathy have been shown to correlate with insulin levels.[191]  
Likewise, hyperinsulinemia and insulin resistance have been associated with 
podocyte injury in Zucker rats.[192]  Only recently has podocyte injury been 
recognized as an early event in IR/diabetic nephropathy.[193]  Our DH-IR pig model 
is consistent with this early finding.   
Both mesangial matrix expansion and podocyte injury are thought to lead to 
glomerular hypertrophy.[194]  We have shown an increase in glomerular size (Table 
4.1) in our DH-IR pigs over FH-IS controls.  Estimated glomerular volumes for the 
DH-IR pigs were increased 1.6 and 1.8 times (UA/C <30 and UA/C >30, respectively) 
those of the FH-IS control pigs.  This is also consistent with data from rhesus 
monkeys showing an association between glomerular hypertrophy and 
hyperinsulinemia which appeared before the onset of diabetes.[195] 
 
Arteriolar hyalinosis, GBM thickening, and tubulointerstitial fibrosis 
Only DH-IR pigs with UA/C >30 exhibited the most abnormal finding of renal 
nephropathy including arteriolar hyalinosis, GBM thickening, and tubulointerstitial 
fibrosis.  While GBM thickening was noticed by light microscopy in two of these pigs, 
electron microscopy offers relatively few glomeruli for measurements. Therefore no 
significant changes were observed between the means for the two groups of DH-IR 
pigs, although both were significantly thicker than the control pigs.   A combination of 
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 GBM thickening, podocyte pathology, and hemodynamic changes was associated 
with proteinuria and the most abnormal findings of nephropathy, including 
tubulointerstitial fibrosis and tubular atrophy.[196] 
 
Aldosterone and blood pressure 
The associations between insulin resistance, systemic hypertension, the 
renin-angiotensin-aldosterone system (RAAS), and renal disease are well 
established.[197-199]  Both obesity and insulin resistance lead to activation of RAAS 
which in turn contributes to renal injury.  The hormone aldosterone regulates 
electrolyte reabsorption and secretion in the kidneys leading to regulation of blood 
volume and pressure.  Continuous infusing of aldosterone in rats fed a high salt diet 
led to podocyte injury and resultant proteinuria.[200]  It is also suggested that both 
proteinuria and podocyte injury are related to aldosterone signaling in a rat model of 
metabolic syndrome.[201]  Both groups of DH-IR pigs had increased aldosterone 
levels over controls and those with UA/C >30 had the highest values. The potential 
effects of elevated aldosterone are also seen in the decreased numbers of 
podocytes present in the DH-IR pigs.  The contribution of insulin resistance to 
increased blood pressure via the actions of aldosterone is also observed in the DH-
IR pigs. Study pigs with increased aldosterone levels had higher blood pressure than 
those with lower aldosterone levels.  Findings in our IR pigs are consistent with 
those in non-diabetic insulin resistant humans who exhibit higher blood pressure in 
subjects with microalbuminuria.[176]   
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 Obesity 
Obesity may incite insulin resistance as well as add to its severity.  Additional 
similarities between human studies and our findings include increased obesity in 
non-diabetic subjects with microalbuminuria.[176]  When glomerular gene 
expression profiles from obesity related glomerulopathy (ORG) patients were 
compared to normal controls, ORG glomeruli were found to have significant changes 
in genes related to lipid metabolism, inflammatory cytokines and insulin 
resistance.[202]  It is suggested that in addition to alterations in lipid metabolism, the 
upregulation of insulin resistance genes indicates a role for local insulin resistance in 
ORG lesion development.  Another study showed a correlation between insulin 
resistance and decreased podocyte number and density in patients with ORG.[191]   
Weight increased significantly in both groups of DH-IR pigs over the yearlong study 
and backfat was significantly increased at 12 months in the DH-IR pigs with UA/C >30 
compared to DH-IR pigs with UA/C <30.  Other obesity related renal findings in our 
pigs include glomerular hypertrophy (glomerulomegaly), focal segmental 
glomerulosclerosis, decreased podocyte number and density, and GBM thickening.   
 
Study Limitations 
The use of a high fat, high salt diet leads to significant increases in weight 
gain, back fat and insulin resistance.  The use of FH-IS pigs was to provide a control 
with comparable hypercholesterolemia while avoiding the change in metabolic 
parameters associated with a high fat diet.  
The nephropathy seen in the DH-IR pigs resembles perihilar focal segmental 
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 glomerulosclerosis (FSGS).  FSGS presents with perihilar sclerosis in greater than 
50% of glomeruli with segmental lesions, glomerulomegaly is usually present and it 
may be associated with obesity.  In a study of patients with FSGS variants, those 
with perihylar FSGS had the highest frequency of hypertension.[203]  The 
nephropathology seen in the DH-IR pigs with UA/C >30 does resemble perihylar 
FSGS, however, when the other metabolic factors are taken into consideration, an 
insulin resistant/hyperinsulinemic nephropathy seems more likely. 
 
Summary 
Increased insulin levels and insulin resistance have been independently 
associated with chronic kidney disease[19, 175, 176, 204] and are present early in 
the course of renal disease.[180, 205-207]  Our goal was to characterize the extent 
to which functional and anatomic changes occur in our insulin resistant (IR) pigs 
and, most importantly, how closely these changes resemble those found in humans 
with IR.   We have detected UA/C >30 in 9 of 17 (52%) IR pigs and 8 of these 9 
(88.8%) had renal lesions consistent with insulin resistance.  Hyperglycemia is a 
major determinant of risk for diabetic nephropathy in humans.[208, 209]  Although 
our IR pigs did not develop overt diabetes, all had increases in insulin resistance and 
DH-IR pigs with UA/C >30 had increases in fructosamine at some point during the 
study consistent with an increase in glucose to some degree.  Notably, insulin 
resistance in humans without diabetes is associated with an increased risk of 
developing chronic kidney disease and one of the key manifestations is 
microalbuminuria.[88-93]  These data suggest that our IR pigs with UA/C >30, 
119 
 120 
moderate blood pressure elevations (at least 140/90), and increased aldosterone 
levels provide a model of the nephropathy found in IR humans without overt 
diabetes and that IR is necessary for initial glomerular changes (mesangial matrix 
expansion and podocyte injury) but insufficient for the nephropathy seen in our pigs 
with albuminuria.  This work provides a model of early (pre-diabetic) renal damage 
that exhibits the associations between insulin resistance, hypertension, and obesity 
that are already established from observational studies in humans. The model 
should prove useful in elucidating mechanisms as well as testing treatment 
strategies for IR/hyperinsulinemic associated chronic kidney disease. 
 
 Chapter 5 
Discussion and Future Directions 
 
Summary 
 Development and characterization of this porcine model of insulin resistance 
and hyperlipidemia has identified an animal model that 1-develops severe and 
diffuse coronary and aortic atherosclerosis with morphology that recapitulates the 
disease phenotype that develops in IR humans, and 2-develops renal histopathology 
when albuminuria is present that is consistent with human insulin resistant/pre-
diabetic nephropathy.  Additionally, we have identified a promising set of aortic 
endothelial cell genes that can be used for further investigation of the endothelial 
dysfunction seen in these pigs and to develop novel methods for the noninvasive 
detection of endothelial dysfunction that occurs during atherogenesis in a relevant 
animal model.  To our knowledge, this is the first description of an animal model of 
insulin resistance and hyperlipidemia that exhibits all of these components. 
 
 
Cardiovascular Disease 
 Feeding insulin resistant pigs a high fat, high salt diet induced two 
atherosclerosis phenotypes:  a severe and diffuse coronary and aortic 
atherosclerosis and a moderate coronary and aortic atherosclerosis.  Surprisingly, 
the presence of insulin resistance alone did not correlate with the severity of 
 
 atherosclerotic disease.  The most significant finding was that pigs in the severe 
atherosclerosis group had significantly higher oxLDL along with greater increases in 
fructosamine and aldosterone levels when compared to the moderate 
atherosclerosis group.  Hence, the severity of atherosclerosis development may be 
enhanced through changes in oxidative stress that accompany feeding a high fat, 
high salt diet.  Furthermore, the atherosclerotic lesions present in these pigs were 
morphologically identical to those found in human coronary atherosclerosis[28, 30] 
and included fibrous caps, intimal thickening, calcium deposits, medial thinning, 
hemorrhage, and necrosis. 
 
Endothelial Cell Gene Expression 
 Differential gene expression studies from both normal and atherosclerotic 
endothelium of the severe and moderate disease groups identified genes involved in 
cell adhesion, migration, and proliferation or transcription and translation that were 
either significantly up- (PTPRM, FAM5C, CLOCK, MYCPBP, LPHN2, HIPK2) or 
down (TMSB4X, EIF2S3, JARID1C) -regulated in the severe disease group.  Three 
genes (MERP-1, RABGAP1L, COL12A1) were uniquely expressed in atherosclerotic 
endothelium of the severe disease group and one gene (SERPINI1) was uniquely 
expressed in normal endothelium of the severe disease group.  These have been 
shown in other studies and cell systems to be involved in cell adhesion[163, 166, 
169, 172, 173], proliferation[165], and differentiation[165] as well as tissue 
remodeling[164].  Their identification provides a basis for further investigational 
studies on the role of oxLDL in endothelial dysfunction and atherosclerosis. 
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Renal Dysfunction 
Feeding insulin resistant pigs a high fat, high salt diet also resulted in two 
different renal phenotypes.  Approximately half of the animals exhibited albuminuria 
(UA/C >30), while the other half showed minimal or no albuminuria (UA/C <30). Both 
groups exhibited mesangial matrix expansion, decrease in podocyte density, and 
glomerulobasement membrane thickening, however, only the group with UA/C >30 
had moderate elevation in blood pressure, and persistent elevations in aldosterone 
levels as well as glomerulosclerosis, tubulointerstitial fibrosis, and arteriolar 
hyalinosis – findings consistent with those seen in humans with insulin 
resistant/diabetic nephropathy.[181-183]  Both groups also had a similar degree of 
hyperinsulinemia, decrease in insulin sensitivity, weight gain, backfat, lipid profiles, 
and inflammatory markers.   The group with UA/C >30 provides a model of early (pre-
diabetic) renal damage that exhibits the associations between insulin resistance, 
hypertension, and obesity that are already established. This model should prove 
useful in elucidating mechanisms as well as treatment strategies for 
IR/hyperinsulinemic associated chronic kidney disease. 
 
Additional Studies 
Endothelial dysfunction can lead to a host of hemostatic, thrombotic, 
inflammatory and other factors that may or may not have potential in predicting the 
onset and severity of atherosclerosis.[210, 211]  Many of these factors have also 
been associated with diabetes mellitus and insulin resistance and may be predictive 
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 of cardiovascular events in these patients.[212-214]  It has been suggested that in 
IR-DM patients, activation of coagulation is driven by increases in glucose whereas 
impairments in fibrinolysis are driven by insulin levels.[215]  Initial characterization of 
this model sought to evaluate selected plasma markers of coagulation, fibrinolysis, 
and endothelial cell dysfunction and their correlation with glycemic control, 
inflammatory markers, and atherosclerosis in hypercholesterolemic, 
hyperinsulinemic pigs.  aPTT, PT, VWF and fibrinogen levels were assessed.  No 
differences were seen between atherosclerosis groups for any of these parameters.  
However, aPTT for all pigs did significantly shorten (compared to baseline) at all 
time points measured over the course of the year-long study (Figure 5.1) suggesting 
some degree of change in coagulation most likely due to the hyperlipidemic state 
created by the high fat diet. This is supported by the finding that the greatest 
decreases occurred in the first 3 months and leveled off thereafter. There were no 
differences in PT, VWF, or fibrinogen over the course of the year.  Due to a lack of 
any variation in these parameters between the two atherosclerotic groups, we did 
not further pursue coagulation or fibrinolytic changes. 
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Figure 5.1 – aPTT measurements in DH-IR pigs.  aPTT was measured by clot 
assay on the ST4 (Diagnostica Stago, Parsippany, NJ) using plasma from all 18 
study pigs at baseline, 1, 2, 3, 6, and 12 months.  Results are mean ± SD for all pigs 
at each time point.  Baseline values fall within normal ranges of those reported for 
pigs.[216] 
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 Future directions 
 A second study is currently underway to confirm and strengthen the data 
presented here.  An additional 20 pigs have been entered into a comparable year-
long high fat, high salt diet study.  Furthermore, 5 pigs have been added that will not 
receive high fat, high salt diet (only standard pig chow) and therefore serve as 
normocholesterolemic controls.  By using a combined total of 38 animals with insulin 
resistance and hyperlipidemia we should be able to 1-follow elevations in oxLDL, 
fructosamine, and aldosterone to more accurately predict the extent to which they 
correlate with atherosclerosis severity, 2- increase the number of aortic EC RNA 
samples collected in order to substantiate genes identified in Chapter 3 and 3-to 
better monitor renal status in order to determine specificity and sensitivity with which 
renal histopathological findings may be predicted by elevated urinary albumin. In 
order to better assess any renal insufficiencies over the course of the year, urine is 
being collected monthly.  This will hopefully allow us to better evaluate the time of 
onset, frequency and degree of albuminuria.   
 
Pigs from both studies are from a mixed genetic background, including 
Spotted Poland/China and Yorkshire crosses as well as pigs that are heterozygous 
for familial hypercholesterolemic (one normal allele and one FH allele).  As 
mentioned in previous chapters, cholesterol levels at baseline and while ingesting a 
high fat, high salt diet are comparable for both groups of pigs and heterozygous 
familial hypercholesterolemic (HFH) pigs do not exhibit hypercholesterolemia unless 
they are fed a high fat diet.  Nonetheless we controlled for this genotype in our 
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 analyses of severity of atherosclerosis and metabolic variables.  At this point we do 
not feel that the presence of one FH allele is influencing the data presented.  The 
present study of 18 pigs contains 10 normal and 8 HFH pigs and the additional study 
of 20 pigs contains 6 normal and 14 HFH pigs.  This gives us a combined total of 16 
normal and 22 HFH.  Based on statistical power analyses from results of the first 18 
pigs, the addition of 20 more pigs should render a sufficient number of animals to 
determine if the FH allele is exerting an influence on atherosclerosis severity or 
metabolic variables.  The inclusion of 5 normocholesterolemic (2 normal and 3 HFH) 
controls will allow us to look at the effects of hyperinsulinemia/insulin resistance 
independent of increases in cholesterol and changes in lipoprotein profiles. 
 
 Additionally, this pig model has already been used in pilot studies for the in 
vivo detection of nonstenotic plaques and the material assessment of these plaques 
via a novel imaging method known as acoustic radiation force impulse (ARFI) 
ultrasound.[217]  These studies have shown ARFI detection of nonstenotic plaques 
not revealed by conventional B-mode ultrasound as well as correlations between 
elastin and collagen contents and peak displacement and recovery time 
parameters.[217]  During the second study (mentioned above) all 25 pigs (20 diet 
fed and 5 control) will be monitored via ARFI for changes in femoral artery 
atherosclerosis over the course of the year.   Images taken at 12 months will be 
compared with ex vivo measurements of atherosclerosis and histological 
assessments of vessel material content.  Results of ARFI assessments will allow us 
to monitor the progression of atherosclerosis over the year as well as to determine if 
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 a more aggressive atherosclerosis phenotype is associated with increases in oxLDL 
and fructosamine. 
  
This work supports the long range goal of this laboratory: to provide the 
scientific community with a well-characterized, reproducible animal model of insulin 
resistance that develops human-like coronary and aortic atherosclerosis and kidney 
disease.  This model will not only be of considerable value for mechanistic studies 
that investigate the underlying pathophysiology but also for intervention studies to 
test new therapeutic approaches. 
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